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ABSTRACT
Many phenotypic traits are heritable, but the exact genetic causes are difficult to
determine. A common approach for disentangling the different genetic factors is to
conduct a “genome-wide association study” (GWAS), where each single nucleotide
variant (SNV) is tested for association with a trait of interest. Many SNVs for
complex traits have been found by GWAS, but to date they explain only a fraction
of heritability of complex traits. In this dissertation, we propose novel optimization-
based and multiple testing procedures for variant set tests.
In the second chapter, we propose a novel variant set test, convex-optimized
SKAT (cSKAT), that leverages multiple SNV annotations. The test generalizes SKAT
to convex combinations of SKAT statistics constructed from functional genomic
annotations. We differ from previous approaches by optimizing kernel weights with
a multiple kernel learning algorithm. In cSKAT, the contribution of each variant
to the overall statistic is a product of annotation values and kernel weights for
annotation classes. We demonstrate the utility of our biologically-informed SNV
weights in a rare-variant analysis of fasting glucose in the FHS.
v
In the third chapter, we propose a sequential testing procedure for GWAS that
joins tests of single SNVs and groups of SNVs (SNV-sets) with common biological
function. The proposed procedure differs from previous procedures by testing genes
and sliding 4kb intergenic windows rather than chromosomes or the whole genome.
We also sharpen an existing tree-based multiple testing correction by incorporating
correlation between SNVs, which is present in any SNV-set containing contiguous
regions (such as genes).
In the fourth chapter, we present a sequential testing procedure for SNV-sets that
incorporates correlation between test statistics of the SNV-sets. At each step of the
procedure, the multiplicity correction is the number of remaining independent tests,
making no assumption about the null distribution of tests. We provide an estimator
for the number of remaining independent tests based on previous work in single-
SNV GWAS and demonstrate the estimator is valid for sequential procedures. We
implement the proposed method for GWAS by sequentially testing chromosomes,
genes, 4kb windows, and SNVs.
vi
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1Chapter 1
Introduction
1.1 Genome-wide Association Studies
Many phenotypic traits are heritable, but the exact genetic causes are difficult to
determine. A common method for disentangling the effects of different genetic
factors is to perform a “genome-wide association study” (GWAS), where each single
nucleotide variant (SNV) is tested for association with a trait of interest. GWAS for
complex traits are limited in several respects. The human genome contains millions
of SNVs, which can lead to many spurious association if SNV associations are tested
at the nominal significance level α = 0.05. Single variant tests are instead evaluated
at a stringent significance level α = 5 × 10−8 (Goeman & Solari, 2014) to control
the probability of identifying at least one spurious association (familywise error
or FWER), which can mask many true associations between causal variants and
the trait. In addition, most causal variants also contribute weakly to trait variance,
making their effects difficult to distinguish from random variation (Richards et al.,
2015). In this introductory chapter, we briefly describe two active areas of statistical
genetics that seek to address these problems and then present our proposedmethods
in the context of current research.
21.2 Variant Set Tests
Statistical power to detect association between a causal SNV and a trait increases
with effect size (strength of association) and minor allele frequency (MAF). Most
GWAS have insufficient sample size to detect the effects of low-frequency SNVs
(MAF ≤ 5%) in the population. Variant set tests address this issue by jointly testing
the association between all SNVs in a set (i.e. gene) with the trait, thereby increasing
the combined effect size and minor allele frequency. Strategies for testing variant
sets include burden tests that combine SNVs into a single burden variable (Li &
Leal, 2008; Morgenthaler & Thilly, 2007; Madsen & Browning, 2009), marginal tests
that create a composite statistic from marginal association statistics for each SNV
(Conneely & Boehnke, 2007; Wu et al., 2011; Barnett et al., 2017), and regression tests
that jointly test SNVs selected by variable selection methods (Klasen et al., 2016;
Buzdugan et al., 2016a).
The burden approach tests for association between the trait and the weighted
sum of SNVs in the set (or burden score). Burden tests are most powerful when
the weights are equal to SNV effects on the trait (Minica et al., 2017), but estimated
effects for rare variants can be unreliable. As a consequence, numerous burden
methods have been developed to find better weights for rare SNVs. Li and Leal
(Li & Leal, 2008) proposed the combined multivariate and collapsing (CMC) test,
which aggregates SNVs into multiple groups based on MAF, creates burden scores
within each MAF group, and jointly tests association between burden scores and
the trait. Han and Pan (Han & Pan, 2010) propose a data-adaptive sum test that
uses single-SNV tests to determine direction of effect for each variant and assigns
SNV weights based on signs of the single-SNV effects. Hoffman et al. (Hoffmann
et al., 2010) propose another data-adaptive test that assigns SNV weights based on
3both the sign and magnitude of single-SNV effects. Even with adaptive weights,
burden tests generally have poor power when SNVs have different directions of
effect, leading to the adoption of methods that combine marginal test statistics and
are powerful for testing a mix of protective and deleterious SNVs.
The minP test is a particularly useful composite marginal test. Originally pro-
posed by Conneely and Boehnke (Conneely & Boehnke, 2007), the minP statistic is
the minimum p-value of all association tests for SNVs in the set. Given a continuous
trait, single-SNV test statistics are asymptotically multivariate normal, allowing
for analytical computation of a p-value for the minP statistic from a multivariate
normal distribution with covariance matrix proportional to the correlation matrix
for SNV genotypes. The minP test is powerful for testing SNV-sets with a single
causal SNV and has often been used as a benchmark for more recent variant-set
tests. When multiple SNVs in a set are causal, however, minP is less powerful than
tests that combine information from all SNVs. One such alternative is the Sequence
Kernel Association Test (SKAT), proposed by Wu et al. (Wu et al., 2011), which has
become ubiquitous in rare variant association studies.
The SKAT statistic is a weighted sum of score statistics for each trait-SNV
association. SNV weights are assigned a priori based on beliefs about the SNV
effects, such as prior evidence that rare SNVs have larger effect sizes due to natural
selection. Under the SNV-set null hypothesis, the SKAT statistic is asymptotically
distributed as a weighted sum of independent χ21 variables, with weights equal to
non-null eigenvalues of the between-SNV correlation matrix. The SKAT originally
proposed by Wu et al. (Wu et al., 2011) is less powerful than burden tests for
testing SNVs that have the same direction of effect. SKAT-O, proposed by Lee et
al. (Lee et al., 2012), addresses this shortcoming by taking the convex combination
of SKAT and burden test statistics, resulting in a test that is powerful regardless of
4the direction of SNV effects. The SKAT family of tests has poor power when causal
SNVs are uncorrelated with non-causal SNVs (Barnett et al., 2017).
The Generalized Higher Criticism (GHC) test was recently proposed by Barnett,
Mukherjee, and Lin (Barnett et al., 2017). Power of the GHC test is less dependent
on SNV correlation structures than SKAT. The GHC counts the number of marginal
SNV z-test statistics exceeding a fixed threshold (in absolute value). The threshold
is selected to maximize the standardized count. The GHC has greater power than
minP in most SNV-sets and has greater power than SKAT when causal variants are
uncorrelated other other SNVs.
Choice of SNV-set test is critical to power, but the parameters determining
relative power of the procedures are usually unknown, such as the proportion
of causal variants or the magnitude of causal variant associations. As a catchall
solution, an omnibus approach has been commonly used, where p-values are
calculated for separate methods and the test statistic is equal to the minimum
p-value for all methods. Omnibus tests include multi-kernel SKAT (MK-SKAT)
(Wu et al., 2013), multi-kernel SKAT-O (He et al., 2017), and the GHC omnibus test
(Barnett et al., 2017). In MK-SKAT and multi-kernel SKAT-O, SKAT or SKAT-O
statistics and their corresponding p-values are computed using different sets of
SNV weights. The MK-SKAT statistic is then defined as the minimum p-value of
all p-values computed. The GHC omnibus statistic is the minimum p-value of
SKAT, minP, and GHC tests for a SNV-set. Much like the data-adaptive burden
tests, omnibus tests for SKAT and GHC are evaluated through resampling of trait
values and are prohibitively slow for computing small p-values.
51.3 Multiple Testing Methods for Variant-Sets
Although SNV-set tests detect joint association between SNVs and a trait, they do
not identify which individual SNVs are associated with the trait. Geneticists will
often check functional genomic databases and biomedical literature to identify likely
causal variants within a trait-associated SNV-set. In large SNV-sets or SNV-sets
in intergenic regions without known function, however, there may be too many
potentially associated SNVs and not enough functional genomic information to
identify likely causal variants. To address this issue, sequential rejection procedures
have been developed to test each SNV within large SNV-sets after the SNV-set has
been found associated with the trait, termed (Goeman & Solari, 2010). Sequential
rejection procedures increase significance levels for SNVs in SNV-sets that are found
to be associated with the trait. Using these procedures, the significance level for
individual SNVs in trait-associated windows may be less conservative than the
typical GWAS α = 5× 10−8.
Goeman et al. proposed sequential rejection strategies for genetic association
studies (Goeman & Finos, 2012), in which hypotheses for SNV-set and single-SNVs
are tested in a logical sequence. The null hypothesis for a SNV-set is true when no
SNVs in the set are associated with the trait, or in other words when at least one
SNV hypothesis is false. Thus, a single-SNV test can be less stringent when the
parent SNV-set is significantly (jointly) associated with the trait. There are fewer
SNV-sets tested than SNVs, so the SNV-set significance level inherited by SNVs is
usually less conservative than the genome-wide significance level of α = 5× 10−8.
Meijer and Goeman (Meijer et al., 2015) later improve the method to account for
overlap between SNV-sets. Both works used a variant-set test related to SKAT.
Klasen et al. (Klasen et al., 2016) and Buzdugan et al. (Buzdugan et al., 2016a)
6combine least absolute shrinkage and selection operator (LASSO) selection of SNVs
with a sequential rejection procedure. For each SNV-set, they use LASSO to select
SNVs in the SNV-set that could potentially be associated with the trait, then jointly
test the selected SNVs for association with the trait. The rest of their procedure fol-
low the inheritance rules for logically related hypotheses proposed by Meinshausen
Meinshausen (2008) and Goeman Goeman & Finos (2012). All of the sequential
procedures described are conservative when SNV-sets are correlated, and they have
rarely been used in recent GWAS.
1.4 Dissertation Outline
In this dissertation, we present novel statistical methods for jointly testing SNV-
sets and for identifying which SNVs in the set contribute to a trait. Each chapter
contains a methodological development, simulations evaluating the method, and
an application to fasting glucose in the Framingham Heart Study (FHS).
In the second chapter, we propose a novel variant set test, convex-optimized
SKAT (cSKAT), that leverages multiple SNV annotations. The test generalizes SKAT
to convex combinations of any number of SKAT statistics—as opposed to the SKAT-
O convex combination of a burden and SKAT statistic. Like the multi-kernel SKAT
tests, kernels for cSKAT are constructed from each annotation class, which we select
from functional genomic annotations such as histone modification. We differ from
previous SKAT approaches by optimizing kernel weights through a multiple kernel
learning algorithm and evaluating our cSKAT test statistic through data-splitting.
In cSKAT, contribution of each variant to the overall effect of the SNV-set can be
computed directly from weighted sum of annotation values. We demonstrate the
utility of our biologically-informed SNVweights in a rare-variant analysis of fasting
7glucose in the FHS.
In the third chapter, we propose a sequential testing procedure for GWAS that
joins tests of single SNVs and groups of SNVs (SNV-sets) with common biological
function. SNVs are aggregated into SNV-sets at different levels—genes (or 32kb
windows), sub-regions (exons/introns/4kb windows), and single SNVs—and each
set of SNVs is tested for joint association with the trait. We assign a significance
level for each SNV-set that is proportional to the fraction of independent SNVs
in the set. The proposed procedure differs from previous work in two respects.
Instead of testing the largest SNV-sets, such as genomes or chromosomes used in
previous procedures, we start with genes and sliding 4kb intergenic windows—a
SNV aggregation strategy which has been used successfully in rare variant associa-
tion studies (Morrison et al., 2013, 2017). We also improve Meinhausen’s tree-based
testing procedure Meinshausen (2008) by incorporating correlation between SNVs.
In the fourth chapter, we present a sequential testing procedure for SNV-sets
that incorporates correlation between test statistics of the variant sets. For an
ordered set of p-values p1, p2, · · · , pM for tests t1, t2, · · · , tM of null hypotheses
H0,1, H0,2, · · · , H0,M , we compute an adjustment factor for the ith test,mi, which is
the effective number of independent tests with p-values at least as large as pi. Our
procedure tests the null hypotheses in order, rejecting the ith hypothesis at signifi-
cance level α/mi and stopping when a hypothesis fails to be rejected. Our proposed
method is a sequential improvement to the Bonferroni correction with effective
number of independent tests (Bonf-Meff), a method commonly used to control
FWER in GWAS. Our contributions are an estimator for the number of remaining
independent tests based on previous work in single-SNV GWAS (Gao et al., 2008;
Hendricks et al., 2014), a sequential testing procedure based on Meff (BH-Meff), and
a tree-based implementation of BH-Meff for hierarchically structured hypotheses.
8In the fifth chapter, we summarize our findings and discuss possible future
work.
9Chapter 2
Convex Combination Sequence Kernel
Association Test for Rare Variant Studies
2.1 Introduction
Many phenotypic traits are heritable, but the exact genetic causes are difficult to
determine. A common method for disentangling the effects of different genetic
factors is to perform a “genome-wide association study” (GWAS), where each single
nucleotide variant (SNV) is tested for association with a trait of interest. However,
the allele frequency of single variants can strongly influence the power of single
variant tests, resulting in low power to detect the effects of rare (MAF ≤ 0.5%) and
low-frequency (0.5% < MAF ≤ 5%) SNVs. Variant set tests address this issue by
aggregating SNVs into SNV-sets, increasing the cumulative (or combined) MAF
of all variants being tested. SNVs within a set are weighted by their hypothesized
effect on the trait or disease risk as a function of available annotation, e.g. a function
of MAF giving more weight to rarer SNVs.
Fixed weights may misspecify the contribution of the variants and lower the
power of the variant set test (Minica et al., 2017). Several variance-component tests
address this problem by choosing a single best annotation (MK-SKAT) (Urrutia
et al., 2016) or finding an optimal combination of two weighting schemes (SKAT-O)
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(Lee et al., 2012). The first approach ignores complementary information from
annotations that are not selected, while the second approach is restricted to two
weighting schemes. We instead propose an optimal combination of any number
of SNV weights and then test whether the combined SNVs are associated with the
trait.
Another concern in rare variant analysis is the choice of SNV to include in
the SNV-set, which is critical to the power of the association test. If the SNV-set is
chosen poorly, the association signals from causal SNVs within the set are diluted by
included SNVs unrelated to the trait. Genes or gene sets (e.g. pathways) are natural
SNV-sets, but no such organizing principle exists for SNVs located outside of genes,
called “intergenic” SNVs. We adopt the approach of a previous analysis, where
intergenic SNVs were aggregated within 4000 base-pair (4kb) windows with 50%
overlap (Morrison et al., 2013, 2017), and further screen SNVs using annotations
with potential biological relevance to fasting metabolism (Goldstein & Hager, 2015).
Our method optimizes composite SNV weights from the multiple annotations, such
that SNVs unrelated to the trait (through the annotations) are assigned low (or 0)
weight and are effectively excluded from the SNV-set test.
2.2 Materials and Methods
Our method is built on the SKAT test (Wu et al., 2011), a variance component test
for the association between a set of SNVs and a trait. We briefly describe the SKAT
approach for testing SNV-sets. We then introduce our proposed method, cSKAT,
to find the optimal convex combination of candidate SKAT statistics. Because of
the optimization involved, the cSKAT statistic null distribution must be assessed
empirically. We offer a method for doing so, based on data splitting. We also present
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a biologically informed approach to constructing candidate kernels.
2.2.1 Convex-optimized SKAT (cSKAT)
Denote y by a (n × 1) vector of trait values for n subjects; X as a (n × d) design
matrix of non-genetic covariates and β as a (d × 1) vector of non-genetic effects,
both including an intercept;G as a (n×m) matrix of SNV genotypes or dosages; and
Gi· is the (m× 1) genotype vector for the ith subject, Gij is the ith subject’s genotype
for the jth variant (0 ≤ Gij ≤ 2). Assume a generalized linear mixed effects model
relating trait to SNV genotypes:
g(E(y)) = Xβ + h (2.1)
where the link function g is the identity link for continuous traits or logit link for
binary traits and h = (h(G1·), · · · , h(Gn·))T is an (n× 1) vector for the genetic effect
on the subject’s trait, and function h(·) lies in a functional space generated by a
positive-semidefinite kernel function k(· , ·) that satisfies Mercer’s condition (Cris-
tianini & Shawe-Taylor, 2000). The kernel function, k(Gi·, Gj·), measures similarity
between the ith and jth subjects based on their SNV genotypes in the SNV-set.
The SKAT approach assumes h is distributed N(0, τK), where τ is a variance
component indexing the effect of the SNV-set and K is a known kernel matrix with
entries defined by a kernel functionKij = k(Gi., Gj.). SKAT (Wu et al., 2011) tests
the null hypothesis for the SNV effects, H0 : τ = 0:
Q =
(y − yˆ0)TK(y − yˆ0)
φˆ0
(2.2)
where yˆ0 = [g−1(βˆT0X1), · · · , g−1(βˆT0Xn)] is the predicted trait from non-genetic
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covariates and φˆ0 and βˆ0 are maximum likelihood estimates of dispersion parameter
and non-genetic effects under H0, respectively. When y is continuous, φˆ0 = σˆ20 is
the residual variance of y after accounting for non-genetic covariates, and when y
is binary, φˆ0 = 1.
Here we embed functional genomic elements, or annotations, directly in the
Sequence Kernel Association Test (SKAT) and weight the annotations based on their
potential relevance to the trait. Given L candidate annotations, let Q` and K` be the
`th candidate SKAT statistic and kernel matrix, and γ` be the convex weight such
that {γ : ∑L`=1 γ` = 1,γ ≥ 0}. The convex SKAT (cSKAT) statistic is defined as a
convex combination of candidate SKAT statistics:
Qγ =
L∑
`=1
γ`Q` =
(y − yˆ0)T (
∑L
`=1 γ`K`)(y − yˆ0)
φˆ0
. (2.3)
Hence, the cSKAT statistic is defined through a convex combination of kernels,
{K : K = ∑L`=1 γ`K` , ∑L`=1 γ` = 1,γ ≥ 0}. We describe how to construct these
kernels from functional genomic annotation in Section 2.2.3, how to estimate the con-
vex weights in Appendix A, and how to evaluate the test statistic null distribution
below.
When the combination weights, γ, are fixed or optimized on an independent
set of data, the null distribution of Q is a weighted sum of independent χ2 vari-
ables,
∑J
j=1 λjχ
2
1, where λj are eigenvalues of (1/φˆ0)P
1
2 (
∑L
`=1 γ`K`)P
1
2 , P = V −
V X(XTV X)−1XTV is the variance of residuals (y − yˆ0), and V = σˆ20In for continu-
ous traits and In is an (n×n) identity matrix or V = diag[yˆ01(1−yˆ01), · · · , yˆ0n(1−yˆ0n)]
for binary traits and yˆ0i = logit−1(βˆT0Xi) is the estimated probability that subject i is
a case underH0. Asymptotic p-values can be computed analytically with the Davies
method (Davies, 1980) or approximated with high accuracy with the saddlepoint
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method (Kuonen, 1999).
When the combination weights, γ, are optimized from the same data used for the
test, Q can be evaluated through permutation testing. In a permutation test, the test
statistic null distribution would be approximated by fully resampling the observed
traits without replacement (i.e. permutation) and recomputing the test statistic for
each permutation of trait values. Permutations are computationally burdensome
and are difficult to implement for dependent individuals, such as relatives in the
Framingham Heart Study. Due to these limitations, we instead use (single) sample-
splitting in our simulations and analysis, where weights are estimated in a subset
of individuals and the tests are performed in the remaining individuals. Multiple
sample splits may be used to improve power and reproducibility (Meinshausen
et al., 2009).
2.2.2 SNV Annotations
In our analyses, we use four classes of annotation: SNV MAF and three ENCODE
annotations (ENCODE Project Consortium et al., 2012), which include signals of
functional genomic elements along the genome (see Table 2.1).
Table 2.1: SNV Annotations
Class (`) # Features Type [Min, Max] Source
Open Chromatin 1 continuous [0, 1000] ENCODE
Transcription Factors 11 continuous [0, 1000] ENCODE
Histone Modifications 2 continuous [0, 1000] ENCODE
SKAT MAF weight 1 continuous [0, 25] fBeta(1,25)(MAF )
Each ENCODE signal (scaled 0-1000) is derived from chromatin immunoprecip-
itation sequencing (ChIP-seq) of a specific DNA-binding element in a specific cell
type. For example, Forkhead box protein A2 (FOXA2) has a non-zero number of
reads mapping to genomic regions in red blood cells, cancer cells, and other cell
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types. Read counts at each genomic locus are normalized, compared against the
null distribution, and transformed into false discovery rates (q-values). The signals
provided by ENCODE are q-values rescaled to 0-1000 to facilitate visualization.
For each functional genomic element, such as FOXA2, we take the maximum
signal over all cell types relevant to a trait. For fasting glucose, we use the maximum
FOXA2 signal at each genomic location in all available red blood cells, β-cells (if
available), and white blood cells. We call this FOXA2 signal vector an annotation
“feature”. We call the collection of all transcription factors (TFs) an annotation
“class”. Only transcription factors and histone modifications related to fasting
metabolism (Goldstein & Hager, 2015) are included in our rare-variant association
study of fasting glucose. We construct one kernel for each class from features in
Table 2.2.
Table 2.2: SNV Annotation Functions
Class Feature Function (abbreviated)
Open Chromatin DNase-seq Peaks Indicator of regions accessible for transcription
TF
CEBP-β Gluconeogenesis
EGR1 Induces CEBP-α when activated by glucagon
ERRα Gluconeogenesis, fatty acid metabolism
FOXA2 Gluconeogenesis, fatty-acid oxidation (FAO), ketogenesis
GR Induces genes encoding fasting-related TFs
HNF4α Maturity-onset Type 1 diabetes, gluconeogenesis
NRF1 Links transcription of metabolic genes to cellular growth
P300 Interacts with PPARγ (regulator of glucose metabolism)
PGC-1α Regulates energy metabolism genes
SREBP-1,2 Lipid homeostasis
TR Metabolic functions of thyroid hormone
HM H3K9Ac Highly correlated with active promotersH3K36me3 Represses aberrant transcription, defines exons
Minor Allele Frequency MAF Due to natural selection, rare SNVs more likely causal
2.2.3 Specification of Kernel Matrices
Any positive semidefinite kernel can be specified forK, though in most rare variant
studies, the weighted linear kernel is used. As its name suggests, the weighted
15
linear kernel rescales each subject’s genotype vector by fixed weights, and its entries
are dot products of these weighted genotypes. Let wk` be the sum of features in
annotation class ` at SNV k (normalized to the unit interval) and Gik be the ith
subject’s dosage of the kth SNV (0 ≤ Gik ≤ 2). The `th weighted linear kernel
function for subjects i and j is:
(K`)ij =
m∑
k=1
w2k`GikGjk . (2.4)
Optimal SNV weights for traits are unknown, so investigators use estimates
based on allele frequencies (i.e. rare alleles are more likely causal due to nat-
ural selection) or predicted functional consequence scores derived from func-
tional genomic elements, such as transcription factors. In rare variant studies, the
most commonly used weight is the Beta(1,25) density evaluated at the SNVMAF,
wk = fBeta(1,25)(MAFk) (Wu et al., 2011). A recent study has also used functional
impact scores from bioinformatics tools (Morrison et al., 2017).
In our extension of SKAT, we find better SNV weights for a trait by optimizing
the kernel. We consider a class of composite kernels, {K : K =∑L`=1 γ`K` , ∑L`=1 γ`
= 1,γ ≥ 0}, from which to select an optimal kernel for the trait. The convex com-
bination weights are optimized through centered kernel-target alignment (Cortes
et al., 2012) to emphasize only annotation classes that are potentially relevant
to the trait (see Appendix A). Before optimization, all base kernels are trace-
normalized and centered by pre- and post-multiplying by an (n × n) centering
matrix, Cn = (In − 1n1Tnn ), where 1n is an (n× 1) vector of 1’s:
K =
CnK˜Cn
tr(CnK˜Cn)
(2.5)
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where K˜ is a raw kernel matrix andK is the trace-normalized and centered kernel.
When all candidate kernels are weighted linear kernels, optimizing the kernel
combination is equivalent to optimizing SNV weights (w = [w1, w2, · · · , wm]) from
convex combinations of annotations {w : wk =
∑L
`=1 γ`wk` ,
∑L
`=1 γ` = 1,γ ≥ 0}.
To ensure γ is interpretable, annotations of each class are normalized to the unit
interval.
2.2.4 Relatedness between Individuals
When individuals are genetically related, such as within families, the trait model
includes a familial random effect (b):
g(E(y)) = Xβ + h+ b (2.6)
where b is a (n × 1) vector for random effects of familial correlation distributed
N(0, σ2bΦ), σ
2
b is the variance component for within-family correlations, and Φ is an
(n× n) relationship matrix based on pedigrees (twice the expected kinship matrix)
or estimated from genotypes (Eu-Ahsunthornwattana et al., 2014).
UnderH0, estimated trait variance is V = σˆ2bΦ+ σˆ
2
0In for continuous traits (Chen
et al., 2013) and V = σˆ2bΦ + diag[yˆ01(1− yˆ01), · · · , yˆ0n(1− yˆ0n)] for binary traits (Yan
et al., 2015), where σˆ2b and σˆ
2
0 are maximum likelihood estimates. The cSKAT statistic
incorporating familial correlation is:
Q = (y − yˆ0)TV −1(
L∑
`=1
γ`K`)V
−1(y − yˆ0) . (2.7)
UnderH0 and for fixed γ (or γ estimated on independent data), the score statistic
Q is distributed as a weighted sum of independent χ2 variables,
∑J
j=1 λjχ
2
1, where
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λj are eigenvalues of P
1
2V −1(
∑L
`=1 γ`K`)V
−1P
1
2 and P = V − X(XTV −1X)−1XT
(Chen et al., 2013; Yan et al., 2015). The subset used to estimate γ should be
independent of the test set for Q. In our FHS application, we select the maximum
number of unrelated FHS participants (Sebro et al., 2017) for the estimation subset
and use the remaining participants for the test set. More generally, independence
between estimation and test subset can be satisfied by sampling families instead of
individuals (Lu et al., 2016), so long as individuals from different families are less
related than cousins twice removed (Yang et al., 2010).
2.2.5 Meta-analysis
To meta-analyze cSKAT over multiple cohorts (or studies), we suggest estimating
kernel weights in a subset of the largest cohort (estimationN ≥ 600) and using these
estimated kernel weights as fixed in the smaller cohorts. Assume a weighted linear
kernel matrix is specified (Ki,i′ =
∑m
k=1w
2
kGikGi′k) and annotation class weights γ
are fixed across cohorts (excluding the subset used to estimate γ). Let γ` be the
annotation weight for class ` (fixed over all studies), wk`s be the `th annotation for
SNV k in study s, and wks =
∑L
`=1 γ`wk`s be the combined weight for SNV k in study
s. The cSKAT statistic in study s can be expressed as a weighted sum of individual
score statistics for each SNV:
Qs =
m∑
k=1
w2ksS
2
ks =
1
σˆ20
m∑
k=1
w2ks[
n∑
i=1
(yi − βˆT0Xi)Gik]2 (2.8)
where m is the number of SNVs in the SNV-set, S2ks =
1
σˆ20
[
∑n
i=1(yi − βˆT0Xi)Gik]2 is
the score statistic for SNV k, and βˆ0 are the estimated non-genetic effects under
H0. When SNV k is missing from study s, we set S2ks = 0. When genetic effects are
homogeneous across studies, such as in single-SNV fixed-effect meta-analysis, the
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meta-analysis test statistic is:
Qmeta =
m∑
k=1
[ ∑
s∈cohorts
wksSks
]2
. (2.9)
The required summary statistics from each cohort are weights for each variant
(wks), the score statistics for each variant (S2ks), and the between-variant relationship
matrix (Ψs). Let Gs be an ns ×ms genotype matrix, Xs be an ns × ds non-genetic
covariate matrix, and Ps be the ns × ns projection matrix accounting for estimation
of non-genetic covariates. The between-variant relationship matrix is defined as:
Ψs = G
T
s PsGs . (2.10)
WhenXs has only an intercept, the between-variant relationshipmatrix is simply
a covariance matrix of the SNVs rescaled by the estimated variance of y. Suppose
SNV weights for each study are arranged in an m × m diagonal matrix Ws =
diag[w1s, · · · , wms]. Then the asymptotic null distribution of Qmeta is a weighted
sum of independent χ2 variables,
∑J
j=1 λjχ
2
1, where λj are eigenvalues ofW1Ψ1W1+
· · · +WsΨsWs (Lee et al., 2013). After convex weights γ are estimated in a subset
and SNV weights wks are computed, software such as seqMeta or rareMetal (Tang
& Lin, 2015) can be used to meta-analyze cSKAT over multiple cohorts (excluding
the estimation subset).
2.2.6 Type I Error and Power
We perform simulations to compare Type I error and power between our proposed
test (cSKAT) and two other SKAT tests: SKAT (Wu et al., 2011) and SKAT-O (Lee
et al., 2012). MK-SKAT (Urrutia et al., 2016) software has yet to be released and, to
our knowledge, is not computationally feasible for these simulations. For cSKAT,
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we create candidate kernels from MAF and three annotation classes from ENCODE:
open chromatin (OC), transcription factors (TF), and histone modification (HM).
For the other tests which are limited to a single annotation, we use only MAF (see
Table 2.3).
Table 2.3: Tests Compared
Test Annotation used
cSKAT (proposed) OC, TF, HM, MAF
SKAT MAF
SKAT-O MAF
We simulate whole genomes for subjects with the software HAPGEN2 using
reference genomes of European ancestry from the 1000 Genomes Project. We adopt
the SNV test aggregation of intergenic regions from a previous analysis, where
intergenic SNVswere groupedwithin 4000 base-pair (4kb) windows (Morrison et al.,
2013, 2017). The tests are performed for each window with observed cumulative
minor allele count (MAC) greater than 20 and evaluated at multiple type I error
levels (α).
To assess type I error (α), we run 1,000 simulations with 1,000 subjects whose trait
is generated from a standard normal distribution yi
iid∼N(0, 1). In each simulation,
we test 20,000 windows, using 500 subjects for optimizing the cSKAT weights
(N0 = 500) and the other 500 subjects for testing at level α (N1 = 500). Because
the weights are optimized on a subset of individuals who are independent from
individuals used for hypothesis testing, p-values are computed from the SKAT null
distribution Q H0∼∑Jj=1 λjχ21, where λj are eigenvalues of (1/φˆ0)P 12 (∑L`=1 γ`K`)P 12 ,
instead of the permutation distribution.
To compare statistical power of the test statistics, we run 100 simulations using
10,000 subjects in 54 windows (of length 4kb) for different trait-generating models.
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The windows selected for power simulations satisfy several criteria:
1. Over half of the SNVs have 2 or fewer non-zero annotations
2. All annotations are present and vary across the window
3. Number of SNVs ≥ 5
4. At least one SNV has unique annotation (i.e. ≥ 1 SNV with OC-only, ≥ 1 SNV
with TF-only, or ≥ 1 SNV with HM-only)
The first condition implies some degree of orthogonality between annotation
classes. In windows with highly correlated annotations, estimated weights are
unstable and difficult to interpret. The other criteria ensure a diverse set of weights
and causal SNVs are included in simulations. All annotation classes must be present
in a window to simulate equal class weights. When 20% of SNVs are causal, at
least 5 SNVs are needed for one causal SNV. The unique annotation condition
ensures less abundant annotations are well-represented in the simulations and do
not always coincide with more abundant annotations.
We evaluate the power of the cSKAT statistic given various sample sizes for esti-
mation and testing. Power for SKAT and SKAT-O are evaluated on the full sample
in each simulation. Let w˜k` be the sum of all annotations of class ` for SNV k normal-
ized to the unit interval. For each window and simulation γ, we select 20% of SNVs
as causal based on annotation, P (SNV k is causal) =
∑4
`=1 γ`w˜k`/
∑m
k=1
∑4
`=1 γ`w˜k`.
We simulate a continuous trait for each simulation with a simple linear model:
y =
m˜∑
k=1
βkgk + ε (2.11)
where m˜ is the number of causal variants in the window, βk is the effect of the kth
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causal SNV specified as βk =
∑4
`=1 γ`w˜k`, and random error ε ∼ N(0, σ2e) where
σ2e is fixed so that SNVs explain 1% of the trait variance, R2window = 1%. Note that
cSKAT weights γˆ are estimated on the kernel-level and differ from the simulation
model γ, which are on the scale of the original data.
We also evaluate the robustness of the cSKAT statistic to partial and complete
misspecification of SNVweights. Let γmissp be the degree of misspecification ranging
from 0 to 1. We select γmissp × m˜ causal variants randomly (without regard for
annotations) and assign them random uniform effect sizes βmissp ∼ U(0, 1). The
remaining variants are selected and weighted for annotation exactly the same
as in Equation (2.11). In these simulations, we define partial misspecification as
γmissp = 0.5 and complete misspecification as γmissp = 1.
SNV annotations wk are fixed (see Table 2.2), while annotation class weights
γ are varied according to Table 2.4. The first scenario assigns equal weight to all
annotation classes: 0.25 to open chromatin (OC), 0.25 to transcription factors (TF),
0.25 to histone modification (HM), and 0.25 to MAF. The second scenario assigns
equal weight to OC and TF, and the last scenario assigns all weight to TF.
Table 2.4: Power Simulation Parameters
R2window γOC γTF γHM γMAF γmissp
1%
0.25 0.25 0.25 0.25 0
0.5 0.5 0 0 0
0 1 0 0 0
1%
0 0 0 0 1
0 0.5 0 0 0.5
0 1 0 0 0
To determine the sample size used for estimating weights in power simulations,
we compare estimated weights (averaged over 54 windows and 100 simulations
per window) across multiple sample sizes (N0 = 100, 200, · · · , 2000). Let γˆ`,n be
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the average estimated weight for annotation ` in sample size n and denote the
(absolute) difference between weights estimated at consecutive sample sizes as
δn =
∑4
`=1 |γˆ`,n − γˆ`,n−200|. We compare cSKAT power with two different estimation
sample sizes, N0, based on criteria δn ≤ 0.1 and δn ≤ 0.05.
2.2.7 Analysis in the Framingham Heart Study
We applied our method to data from the Framingham Heart Study (FHS), an ongo-
ing longitudinal cohort study with detailed medical history, physical examinations,
and medical tests (Dawber et al., 1951). The first 5209 FHS participants, called the
“Original Cohort”, were recruited in 1948. In 1971, a second cohort (“Offspring”)
of 5124 participants was recruited from offspring of the Original Cohort and their
spouses (Kannel et al., 1979). Finally, the Third Generation Cohort (“Gen III”)
consists of 4095 grandchildren of the Original Cohort and children of Offspring Co-
hort spouses whose parents were not in the Original Cohort (Splansky et al., 2007).
While originally developed as a cardiovascular cohort study, the FHS includes many
other traits, such as fasting glucose and various cancers. In our analysis, we tested
associations between ≥8-hour fasting glucose and SNVs in genes or intergenic (4kb)
windows.
We used genetic and trait data for 6419 diabetes-free participants from the
Offspring Cohort at exam 5 and Third Generation Cohort at exam 1. Fasting glucose
residuals were computed within each sex and cohort by regressing fasting glucose
on age and age squared.
We constructed weighted linear kernels from each annotation class in Table
2.2. All features within each class were summed and resulting SNV weights were
normalized to the unit interval. When applying our method, we estimated convex
weights in an unrelated subset of individuals (n=1814) and used the remaining
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individuals (n=4605) to test the association between fasting glucose and SNVs
within genes and intergenic windows. We performed SKAT-O in the full set of
individuals (n=6419). All analyses were run in R version 3.4.3 (R Core Team, 2017)
with the seqMeta package (Arie Voorman, 2013), which implements the famSKAT
method to account for relatedness between participants (Chen et al., 2013).
2.3 Results
2.3.1 Simulation Results
Using data-splitting, type I error (α) of cSKAT was controlled at all levels but
0.05 and was slightly conservative at type I error levels below 0.005 (see Table
2.5). Inflation at α = 0.05 may be due to small sample size. The null distribution
should be evaluated through permutation testing when possible to correct for this
departure from the nominal significance level.
Table 2.5: Type I Error for cSKAT
α Observed Type I Error 95% CI
0.05 0.05163 (0.05153, 0.05173)
0.005 0.00501 (0.00498, 0.05040)
0.001 0.00097 (0.00096, 0.00098)
5× 10−4 4.88× 10−4 (4.78× 10−4, 4.98× 10−4)
1× 10−4 9.23× 10−5 (8.81× 10−5, 9.66× 10−5)
1× 10−5 9.57× 10−6 (8.26× 10−6, 1.10× 10−5)
2.5× 10−6 2.35× 10−6 (1.72× 10−6, 3.11× 10−6)
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Figure 2.1 is a plot of estimated cSKAT weights at different sample sizes for each
simulation scenario. Note that cSKAT weights γˆ are estimated from the variance
component model used for SKAT which differs from the simulation model, and
consequently γˆ do not converge to γ. In all simulation scenarios, estimated cSKAT
weights γˆ converged within 1000 samples for criteria δn ≤ 0.05 and within 600
samples for criteria δn ≤ 0.1.
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Figure 2.1: Annotation weights (γˆ) estimated by cSKAT at sample
sizesN0 = 100, 200, · · · , 2000. We set 20% of SNVs to be causal. Causal
SNVs explain 1% of trait variance (R2 = 1%). In the top panel, all
annotation types contributed equally to the effect size of causal SNVs,
i.e. the effect size for a causal SNV is the mean of all (standardized)
annotations for the SNV. In the middle panel, causal SNV effect size is
a mean of OC and TF (but no other) annotations. In the bottom panel,
effect size is simply the standardized TF annotations.
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Figure 2.2 displays empirical power for cSKAT, SKAT, and SKAT-O computed
at α = 10−8, averaged over the 54 windows and 100 simulations per window.
Power was evaluated for sample sizes N=200 to 2000 (by 100), N=2000 to 5000
(by 500), and N=5000 to 10000 (by 1000) with estimation subset N0 withheld from
the cSKAT test. For most sample sizes (N ≤ 8000), cSKAT had greater power
for the smaller estimation subset (N0 = 600) than the larger estimation subset
(N0 = 1000), indicating a preference for test sample size (N1) over optimality of
weights γˆ. Under all simulated scenarios, cSKAT with N0 = 600 had greater power
than SKAT and SKAT-O in moderately large samples (N ≥ 5000). For smaller
samples (N ≤ 4000), cSKAT was less powerful than SKAT and SKAT-O due to
sample loss from data splitting. Power for cSKAT improved when annotation
weights were more concentrated, with up to 15% higher power than SKAT-O when
transcription factors had a weight of 1.
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Figure 2.2: Power comparison of cSKAT (proposed), SKAT, and SKAT-
O. Empirical power is computed at α = 1× 10−8 and averaged over
54 windows, 100 simulations per window. We set 20% of SNVs to
be causal. Causal SNVs explain 1% of trait variance (R2 = 1%). In
the top panel, all annotation types contributed equally to the effect
size of causal SNVs, i.e. the effect size for a causal SNV is the mean
of all (standardized) annotations for the SNV. In the middle panel,
causal SNV effect size is a mean of OC and TF (but no other) annota-
tions. In the bottom panel, effect size is simply the standardized TF
annotations.
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Figure 2.3 displays empirical power for cSKAT, SKAT, and SKAT-O for different
levels of misspecified SNV weights: complete misspecification (γmissp = 1), partial
misspecification (γmissp = 0.5), and no misspecification (γmissp = 0). When SNV
weights were completely misspecified, cSKAT was less powerful than SKAT and
SKAT-O due to sample loss from data splitting. On the other hand, cSKAT was
robust to partial misspecification, defined as half of causal SNVs being selected
randomly (with random uniform effect) and half of causal SNVs being selected from
SNVs with non-zero TF annotations. In all misspecification scenarios, N0 = 600
samples were sufficient to estimate cSKAT weights. Using more samples in the
estimation subset (N0 = 1000) resulted in lower power because fewer samples were
available for testing (N1 = N −N0).
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Figure 2.3: Power comparison of cSKAT (proposed), SKAT, and SKAT-
O when SNV annotations are misspecified. Power is evaluated at
α = 1 × 10−8 and averaged over 54 windows, 100 simulations per
window. We set 20% of SNVs to be causal, with (γmissp × 100)% of
causal SNVs selected randomly and assigned random effect sizes
between 0 and 1 that are sampled from a uniform distribution U(0, 1).
Causal SNVs explain 1% of trait variance (R2 = 1%). The top panel
shows complete misspecification where all causal SNVs have random
uniform effects. The middle panel shows partial misspecification
where half of causal SNVs have random uniform effects. The bottom
panel shows no misspecification.
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2.3.2 Results in FHS
Our cSKAT test had a low genomic inflation factor (λGC = 1.037) comparable to the
SKAT-O test (λGC = 1.039). The Q-Q plots (see Figure 2.4) indicate the estimation
and test subsets were sufficiently independent for cSKAT.
Figure 2.4: Q-Q plots for cSKAT (proposed) and SKAT-O in the rare
variant analysis on fasting glucose. Minus log base 10 of p-values are
plotted. Genomic control factor λGC is the ratio of median observed χ21
(converted from median p-value) and median expected χ21. 45-degree
line is λGC = 1 with shaded 95% CI
Due to small sample size in FHS (test subset n=4605), we found no genome-
wide significant associations (p < 10−7) between fasting glucose and the tested
regions (see Figure 2.5). However, two of the top cSKAT associations had potential
biological connections to fasting glucose and were undetected by SKAT-O (see
Table 2.6). The strongest association was in chromosome 2 for a region within 20kb
of ROCK2 (cSKAT p = 2.11 × 10−5, SKAT-O p = 0.10), which has been shown to
induce obesity mediated insulin resistance and cardiac dysfunction (Soliman et al.,
2015). In this region near ROCK2, the estimated annotation weights were 1 for
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transcription factors and 0 for all other annotation classes, suggesting the region
may have a regulatory effect on ROCK2. The second highest association was found
in the gene CPLX1 (cSKAT p = 5.26× 10−5, SKAT-O p = 0.39), which has previously
been implicated in glucose-induced secretion of insulin by pancreatic beta-cells
(Abderrahmani et al., 2004). The estimated annotation weights in CPLX1were large
for histone modification (0.296) and minor allele frequency (0.642). The other top
associations had no biological connection to fasting glucose.
Table 2.6: Top cSKAT Associations
Chr Mid-bp Nearest Gene Distance p-value nSNV s γOC 1 γTF γHM γMAFfrom Gene cSKAT SKAT-O
2 11506210 ROCK2 22 kb 2.11× 10−5 0.10 7 0 1 0 0
4 804928 CPLX1 0 5.26× 10−5 0.39 11 0.021 0.041 0.296 0.642
1 222069979 LOC101929771 56 kb 6.14× 10−5 0.74 16 0 0.316 0.440 0.244
3 50476518 CACNA2D2 0 6.49× 10−5 0.03 312 0 0 1 0
4 54857928 RPL21P44 5 kb 9.73× 10−5 0.34 10 0.035 0.458 0 0.506
8 41910691 KAT6A 1 kb 9.88× 10−5 0.08 6 0 1 0 0
1 γOC = estimated weight for open chromatin annotation (0 ≤ γ ≤ 1)
Table 2.7 lists highly annotated SNVs (with cSKAT weight > 40%) in the top
two associated windows. Annotations in Table 2.7 are presented in their original
scale (bounded between 0 and 1000). The cSKAT-estimated SNV weights (wcSKAT =∑4
`=1 γˆ`w`) have been rescaled so all SNV weights sum to 1, and represent the
proportion of trait variance explained by the window that is attributable to the
SNV. In the window near ROCK2, our method attributed 96% of SNV weight to
two SNVs enriched for transcription factors and open chromatin. In CPLX1, 41% of
trait variance explained by the gene was attributed to one SNV located at a histone
modification.
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Table 2.7: SNVs with cSKAT Weight > 40%
Chr bp Gene Major / MAF wcSKAT 1 OC 2
TF HM
Minor CEBP-β FOXA2 HNF4α P300 H3K9Ac
2 11506578 ROCK2 T/C 0.0017 0.48 360 968 752 959 1000 1282 11506743 C/A 0.0022
4 818583 CPLX1 T/A 0.0017 0.41 229 0 0 0 0 922
1 wcSKAT = estimated weight for SNV (0 ≤ w ≤ 1). Proportion of total SNV weight in the gene attributable to the
SNV. The two SNVs in ROCK2 have identical weights because they have the same TF annotation value, and TF
had 100% weight in ROCK2 (i.e. wcSKAT = TF value)
2 Annotations range from 0 (no signal) to 1000 (max signal)
Figure 2.5: Manhattan Plots for our proposed method (cSKAT) and
SKAT-O
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In Figure 2.6, we compare cSKAT and SKAT weights for SNVs in the windows
included in Table 2.6. Both cSKAT and SKAT weights were rescaled to [0, 1] to
facilitate comparisons. SKAT weights were generally uniform, with differences
between cSKAT and SKAT weights driven by extreme cSKAT weights. SNVs with
large cSKAT weights generally had large annotation values and a strong association
with the trait. In two of the six windows, for example, cSKAT assigned the majority
of weight in the window to a few SNVs at a transcription factor binding site and
histone modification, respectively (Table 2.7).
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Figure 2.6: Comparison of SNV weights used in FHS. The y-axis is
the standard SKAT weight. The x-axis is SNV weight estimated by
cSKAT. SNVs in blue have low cSKAT weight (wcSKAT < 0.1), SNVs
in orange have moderate cSKAT weight (wcSKAT ≈ 0.1), and SNVs in
red and brown have high cSKAT weight (wcSKAT ≥ 0.2). Genes and
windows chosen are the top cSKAT associations presented in Table
2.6.
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2.4 Discussion
In this paper, we present a novel method, cSKAT, for optimizing the rare variant
SKAT statistic over multiple potentially relevant SNV annotations. The method has
higher power than SKAT and SKAT-O in large cohorts (N ≥ 5000), can be meta-
analyzed across multiple cohorts (see Section 2.2.5), and provides interpretable SNV
weights that can inform downstream functional experiments.
In FHS, we find a possible association between fasting glucose and rare variants
near ROCK2 (p = 2.1 × 10−5) and within CPLX1 (p = 5.3 × 10−5), genes involved
in obesity mediated insulin resistance (Soliman et al., 2015) and glucose-induced
insulin secretion by pancreatic beta-cells (Abderrahmani et al., 2004), respectively.
In the window near ROCK2, our method assigns 96% of SNV weight to two SNVs
at an active transcription factor (TF) binding site. At these highly weighted loci, the
strongest TF signal is P300, which interacts directly with ROCK2. ROCK2 regulates
the acetyltransferase activity of P300 through phosphorylation (Tanaka et al., 2006).
The second largest TF signals, CEBP-β and HNF4-α, are only indirectly related to
ROCK2, e.g. ROCK2 knockdown has shown to increase gene expression of CEBPD
(Li et al., 2015), which forms heterodimers with CEBP-β. ROCK1, which often shares
functions with ROCK2, interacts with factor HNF4-α (Yoshikawa et al., 2015). There
is no known link between ROCK2 and the other active transcription factor at this
site, FOXA2.
In CPLX1, 41% of trait variance explained by the gene was attributed to one
SNV with high values of histone modification H3K9Ac. H3K9Ac serves an impor-
tant role in transcription and its loss or depletion in promoters can reduce gene
expression. In a recent study, investigators hypothesized that H3K9Ac recruits
proteins downstream of transcription initiation which are needed for the next step
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of transcription (Gates et al., 2017). Replication is required to validate these results
in other cohorts (using the estimated annotation weights from FHS). We will also
examine associations between the loci and other glycemic traits.
Our method has several limitations. Data-splitting allows us to compute p-
values efficiently from the SKAT null distribution but reduces power because
samples are excluded from testing and SNVs are sometimes absent in the estimation
subset. Meta-analysis can mitigate loss of power due to sample loss, and multiple
sample splitting can ensure all SNVs are involved in kernel optimization (Mein-
shausen et al., 2009). Further simulations will be required to evaluate other kernel
optimization schemes for meta-analysis and find the number of sample splits that
balances the increase in power against the increase in computation time.
Another limitation of our method is a priori selection of annotation. All rare
variant tests require a priori specification of annotation, but our method is especially
sensitive to choice of annotation. When annotations are too correlated, the optimiza-
tion problem is not strictly convex and its solution is not unique, which complicates
the interpretation of kernel weights γ (Cortes et al., 2012). To sidestep the corre-
lation problem in this paper, we aggregate annotations by biological classes and
use only annotations related to fasting metabolism. For more extensive annotation
that is highly correlated, we suggest creating orthogonal annotation classes with
principal component analysis (Jolliffe, 2014), i.e. build base kernels from principal
components of a matrix with all SNV annotations.
While we included only four annotation sources in this paper based on their well-
documented involvement in regulating fasting metabolism (Goldstein & Hager,
2015), cSKAT can easily accommodate additional annotations. For example, several
schizophrenia studies have shown rare disruptive variants (nonsense, essential
splice site or frameshift) substantially increase risk for schizophrenia (Purcell et al.,
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2014; Singh et al., 2017; Teng et al., 2018). In these studies, separate analyses
were conducted for disruptive variants and other rare variant sets. Using cSKAT,
the separate analyses could be combined by pooling all SNVs and coding set
memberships as binary annotations (0 for exclusion, 1 for inclusion). The optimized
cSKAT weights would then enable direct comparisons between disruptive variants
and other variant classes. Given rapidly growing and publicly available functional
genomic annotations, adaptive annotation weighting is now an invaluable tool for
pinpointing the biological mechanisms driving trait-window associations.
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Chapter 3
Tree-based Multiple Testing Procedure for
Genome-Wide Association Studies
3.1 Introduction
Many traits are heritable, but it is difficult to determine exactly which genetic
variants are influencing these traits. A common method for disentangling the
effects of different genetic factors is to perform a “genome-wide association study”
(GWAS), where each single nucleotide variant (SNV) is tested for its association
with a trait. Each association test has a small chance of rejecting the null hypothesis
of no association between single nucleotide variant (SNV) and trait when, in fact, a
SNV has no true effect on trait or disease risk. Because millions of SNVs are tested
in GWAS, testing at the nominal significance level (α = 0.05) would result in many
spurious associations. Multiple testing methods have been developed to control the
chance of detecting a spurious association (family-wise error rate or FWER), but
many methods for FWER-control are based on the number of tests performed and
are known to be conservative when tests are dependent Goeman & Solari (2014).
Genome-wide association studies, in particular, contain many dependent tests
because SNVs in linkage disequilibrium (or associated with each other in a popu-
lation) will have correlated measures of association with a trait. Several multiple
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testing methods have been developed for GWAS that leverage dependence between
SNVs to achieve less conservative FWER-control. The most widely used method
exploits correlations between SNVs to compute the effective number of independent
tests (Meff), a measure which can then be used to control FWER through, for exam-
ple, a Bonferroni correction with the effective number replacing the number of tests
(Bonf-Meff) Hendricks et al. (2014). In GWAS, the Bonf-Meff correction translates
to a genome-wide significance level of α = 5× 10−8 for testing common variants
(minor allele frequency or MAF > 5%) Pe’er et al. (2008). By contrast, a traditional
Bonferroni significance level for GWAS with 20 million common SNVs Consortium
et al. (2015) would be more stringent: αBonf = 0.05/(2× 107) = 2.5× 10−9. While
testing at the Bonf-Meff level is an improvement over previous methods for FWER-
control, single-SNV association tests still have low power to detect trait associations
with rare variants (MAF ≤ 1%) and clusters of variants with small effects.
To better identify variants that would otherwise remain undetected in traditional
GWAS, hierarchical testing procedures have been developed which use powerful
tests for the joint association between sets of SNVs and a trait Meijer & Goeman
(2015); Meinshausen (2008); Ramdas et al. (2017). An example application of hierar-
chical test procedures to GWAS may involve the following steps. First, SNVs are
aggregated into SNV-sets of different levels where every lower level set is a subset of
a higher level set (e.g. SNV⊂ gene). Each set at the highest level (e.g. gene) is tested
for joint association with the trait. When a SNV-set is found to be associated with
the trait, each subset at the next level (e.g. exon/intron) inherits the significance
level of the previous test, corrected for the size of the subset. The procedure is
repeated until single SNVs are tested, where the significance level for single SNV
tests is increased based on previous rejections. For example, if SNVs in a gene are
found to be jointly associated with the trait, at least one SNV must be associated
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with the trait, and single SNVs can be tested at a less stringent significance level.
The improvement for single SNV tests comes at a cost, because we must assume the
preceding hypothesis test is correct: if the gene null hypothesis is not rejected, then
we assume no SNVs are associated with the trait and single SNVs are not tested.
Due to this limitation, statistical power of a hierarchical testing procedure depends
strongly on choice of joint association test, selection of SNV-sets, and significance
levels of the SNV-set tests.
We propose a novel hierarchical testing procedure that assigns a significance
level for each SNV-set test in proportion to the fraction of independent SNVs in the
set. The rationale follows from the Bonf-Meff improvement over the Bonferroni
correction. Previous hierarchical testing methods Meijer et al. (2015); Meinshausen
(2008); Goeman & Finos (2012); Klasen et al. (2016) have constructed significance
levels for set tests based on the number elementary hypotheses in the set and, like
the Bonferroni correction, may be conservative when SNVs in a set are correlated. To
assign less stringent significant levels for SNV-set tests when SNVs are correlated,
we incorporate Gao et al.’s estimator for the effective number of independent
tests Gao et al. (2008) in Meinshausen’s tree-based multiple testing procedure
Meinshausen (2008). Our simulations demonstrate the proposed method controls
family-wise error (FWER), is more powerful than Meinhausen’s method when
SNVs are correlated, and is at least as powerful as the Bonf-Meff correction under
many different SNV correlation structures.
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3.2 Methods
3.2.1 Hierarchical Hypotheses
Meinshausen’s multiple testing procedure can be applied to any set of hierarchical
null hypotheses. In Meinshausen’s initial formulation Meinshausen (2008) and
several applications for GWAS Goeman & Finos (2012); Meijer et al. (2015); Meijer &
Goeman (2015); Klasen et al. (2016); Buzdugan et al. (2016b), SNVs are hierarchically
clustered based on linkage disequilibrium such that one large cluster contains all
SNVs in the genome, one cluster contains all SNVs in a chromosome, and so forth
until the smallest clusters contain single SNVs. However, hierarchically testing
large clusters of SNVs can produce uninterpretable results. For example, Buzdugan
et al.Buzdugan et al. (2016b) found significant associations between bipolar disorder
and clusters with thousands SNVs that had no clear connection to the disease.
In this paper, we aggregate SNVs by potential biological function to ensure
all hypotheses tested are interpretable. SNVs in (or around) a gene may affect
the protein through shape, quantity, or other regulatory mechanisms. We divide
genes into three levels of hierarchy: gene, gene subregions, and single SNVs (Figure
3.1). The gene is divided into subregions because SNVs in coded regions (exons)
may affect protein shape, while SNVs in other regions may affect protein abun-
dance or other regulatory functions. Gene subregions include regulatory regions
(promoter/enhancer), 3’ and 5’ untranslated regions (UTR), introns, and exons.
Defining the SNV-sets through biology ensures all tests in the hierarchy are biologi-
cally meaningful and can inform downstream experimental validation.
For convenience, hypothesis refers to a null hypothesis unless otherwise noted.
Following Meinhausen’s notation, we first construct a tree T for each gene (Figure
3.1) from them SNVs in the gene. Each tree consists of a root node (gene), children
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Figure 3.1: Tree of hypotheses in gene
of the root node (sub-regions), and leaves (single SNVs). Let SNVs be represented
by integers 1, . . . ,m with corresponding null hypothesesH = {H0,i : i = 1, . . . ,m}.
Each node in the tree is denoted as a set of SNVs, i.e. the root node with all SNVs
is {1, . . . ,m} and sub-regions with a subset of SNVs are S ⊆ {1, . . . ,m}. The null
hypothesis for a SNV-set S is satisfied only when all SNVs in the set are unrelated
to the trait:
H0,S =
⋂
i∈S
H0,i (3.1)
The tree is constructed such that every pair of SNV-sets (S, S ′ ∈ T ) either have
no intersection (S ∩ S ′ = ∅) or one SNV-set is a subset of the other (S ⊆ S ′).
There is no universally accepted principle for organizing SNVs in intergenic
regions. For SNVs located outside of genes, we investigate a three-level hierarchy
with 32kb intergenic region, 4kb sub-regions, and single SNVs. The 4kb intergenic
regions have been used in previous rare-variant analyses Morrison et al. (2013,
2017).
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Figure 3.2: Tree of hypotheses in intergenic region
3.2.2 Meinshausen’s Multiple Testing Adjustment
In our framework, hypotheses can be evaluated with any test and, in fact, different
tests can be used at each level of the hierarchy. Let pS be the p-value for a test of
H0,S , |S| denote the cardinality or number of SNVs in SNV-set S, and m be the
number of SNVs in the gene. Then the Meinshausen adjusted p-value pSadj is defined
as:
pSadj = p
S m
|S| (3.2)
The adjustment multiplies the SNV-set p-value by the inverse proportion of total
SNVs it contains. The multiplicity adjustment increases with finer resolutions, with
no penalty for the root node ( m|{1,...,m}| = 1) but a Bonferroni adjustment for single
SNVs (m/1 = m). Beginning with the root node, Meinshausen’s procedure rejects
all hypotheses, H0,S , with both adjusted p-value pSadj no greater than significance
level α and rejected parent node. The parent condition is waived for root nodes.
Meinshausen further refines the adjustment using Shaffer’s observation that not
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all combinations of null hypotheses are possible in a hierarchical structure Shaffer
(1986). Because we test only SNVs that belong to SNV-sets with rejected hypotheses,
errors at the SNV-level can only be made if the parent node was falsely rejected.
This means that falsely rejected SNVs are irrelevant to the overall probability of
making at least one error, because an error must have already been made upstream.
Denote the parents of SNV-set S by pa(S) and children by ch(S). Siblings of S are
defined si(S) = ch(pa(S)) \ S, which are the other children of the parent of S. Then
the Shaffer-improvement is defined as:
pSadj = p
S m
|S|Shaffer (3.3)
where the Shaffer SNV-set size |S|Shaffer is given by:
|S|Shaffer =
 |S|, if si(S) has no leaf nodes|S|+ |si(S)|, if si(S) has leaf nodes (3.4)
3.2.3 Proposed Hierarchical Testing Algorithm
When the smallest tested units (leaf nodes) are dependent, such as the case of SNVs
in linkage disequilibrium (LD), Meinshausen’s multiple testing adjustment will
be conservative Hendricks et al. (2014). To incorporate LD between SNVs in the
testing adjustment, we replace all set cardinalities in Equation (3.4) with the effective
number of independent SNVs. Let CS be the correlation matrix of SNV dosage for
SNVs in set S. Then the effective number of SNVs in set S,mS , is the fewest number
of eigenvalues explaining ≥ 99.5% of variation in CS Gao et al. (2008). Denote by
Meff the effective number of SNVs in the gene. Then our proposed adjusted p-value
is:
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pSadj = p
S Meff
|S|eff (3.5)
where the effective SNV-set size |S|eff is given by:
|S|eff =
 mS, if si(S) has no leaf nodesm{S ∪ si(S)}, if si(S) has leaf nodes (3.6)
Our proposed testing algorithm follows the Meinshausen procedure in rejecting
all hypotheses, H0,S , with both adjusted p-value pSadj ≤ α and rejected parent
hypothesis ppa(S)adj ≤ α.
Algorithm 1: Proposed Hierarchical Testing Algorithm
Data: Trait, y
Genotype or dosage matrix for SNVs, G
SNV-sets, S, including sets with a single SNV
1 Estimate effective number of SNVs in tree: Meff
2 for SNV-sets S ∈ T do
3 Jointly test association between SNVs in set S (GS) and trait (y)
4 Compute p-value: pS
5 Compute effective size: |S|eff
6 Adjust p-value: pSadj = p
S Meff
|S|eff
7 end
8 Reject all H0,S where pSadj ≤ α AND ppa(S)adj ≤ α
Weuse a Bonferroni correction to control FWER over gene tests, pgeneadj = # genes×
pgene. Less conservative corrections for the gene tests will improve the power of our
testing procedure, such as sequential methods (Bonferroni-Holm) or the Bonf-Meff
adjustment for SNV-set tests Xu et al. (2014). We demonstrate FWER control over
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the tree in simulations with many different genes and LD structures.
3.2.4 Association Tests for SNV-sets
Hierarchical testing adjustments can be applied to p-values from different tests but
are generally paired with an association test tailored to the application. In GWAS,
a hierarchically adjusted SNV p-value is the maximum of the individual SNV p-
value and regional p-values for all pre-defined regions containing the SNV Meijer
et al. (2015). Consequently, statistical power to detect a causal variant association
depends strongly on choice of regions and regional tests. Previous hierarchical
procedures have used fixed regions, such as hierarchical clusters of SNVs, and tests
for high-dimensional regressions–either LASSO-based screening tests Klasen et al.
(2016) or variance component score tests Meijer & Goeman (2015).
We use a variance component score test, SKAT-O Lee et al. (2013), to generate
unadjusted p-values for our proposed multiple testing adjustment. SKAT-O is a
combination of two joint association tests between trait and multiple SNVs: burden
test Madsen & Browning (2009) and Sequence Kernel Association Test (SKAT) Wu
et al. (2011). First, SNVs are weighted by their hypothesized effect on the trait,
typically a function of minor allele frequency. In the burden approach, trait is
modeled as a function of the weighted sum of SNVs to test the cumulative effect
of SNVs in the region, whereas for SKAT, SNV weights are used to combine score
statistics for each SNV-trait association. The burden test is especially powerful
when many SNVs are causal and affect the trait in the same direction, while SKAT
is more powerful than the burden test when the SNV-set has few causal SNVs and
a mix of protective and deleterious variants. SKAT-O is a convex combination of
the two test statistics with convex weight optimized to minimize overall p-value
Lee et al. (2012).
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In this paper, we use an implementation of SKAT-O for family data. Denote
trait values for the n subjects by (n× 1) vector y; non-genetic covariates by (n× d)
design matrix X and non-genetic effects by (d × 1) vector β, both including an
intercept; SNV genotypes or dosages by (n×m) matrix Gwhere Gi· is the (m× 1)
genotype vector for the ith subject and Gij is the ith subject’s genotype for the jth
variant (0 ≤ Gij ≤ 2); and random effects of familial correlation by (n× 1) vector b
which is distributedN(0, σ2bΦ)where σ
2
b is the variance component for within-family
correlations and Φ is an (n× n) relationship matrix based on pedigrees (twice the
expected kinship matrix) or estimated from genotypes Eu-Ahsunthornwattana et al.
(2014). The generalized linear mixed effects model relating trait to SNV genotypes
is:
g(E(y)) = Xβ + h+ b (3.7)
where link function g is the identity link for continuous traits or logit link for binary
traits and h = (h(G1·), · · · , h(Gn·))T is an (n× 1) vector for the genetic effect on the
subject’s trait with function h(·) lying in a functional space generated by a positive-
semidefinite kernel function k(· , ·) that satisfies Mercer’s condition Cristianini &
Shawe-Taylor (2000). The kernel function, k(Gi·, Gj·), measures similarity between
the ith and jth subjects based on their SNV genotypes in the SNV-set.
Under the null hypothesis for SNV effects, h is distributed N(0, τK), where
τ is a variance component indexing the effect of the SNV-set and K is a known
kernel matrix with entries defined by a kernel function Kij = k(Gi., Gj.). SKAT-O
Wu et al. (2011) tests the null hypothesis for the SNV effects, H0 : h = 0, by testing
the SNV-set variance component H0 : τ = 0. The SKAT-O statistic incorporating
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familial correlation is:
Qγ = (y − yˆ0)TV −1(γKburden + [1− γ]KSKAT)V −1(y − yˆ0) . (3.8)
where yˆ0 = [g−1(βˆT0X1), · · · , g−1(βˆT0Xn)] is the predicted trait from non-genetic
covariates; estimated trait variance underH0 is V = σˆ2bΦ+ σˆ
2
0In for continuous traits
Chen et al. (2013) and V = σˆ2bΦ+diag[yˆ01(1− yˆ01), · · · , yˆ0n(1− yˆ0n)] for binary traits
Yan et al. (2015); βˆ0, σˆ2b , σˆ
2
0 are maximum likelihood estimates under H0;Kburden =
GWb11
TWbG
T is the burden kernel with SNV weights Wb = diag[w
(b)
1 , · · · , w(b)d ];
KSKAT = GWsWsG
T is the SKAT kernel with SNV weightsWs = diag[w
(s)
1 , · · · , w(s)d ];
and 0 ≤ γ ≤ 1 is the combination parameter balancing SKAT and burden test.
The optimal γ is unknown and must be estimated. In practice, this is achieved
by computing the p-value for Qγ at each γ in a grid 0 = γ1 < γ2 < · · · < γb = 1. For
fixed γ, the score statistic Qγ is asymptotically distributed as a weighted sum of
independent χ2 variables,
∑J
j=1 λjχ
2
1, where λj are eigenvalues of P
1
2V −1(γKburden+
[1 − γ]KSKAT)V −1P 12 and P = V − X(XTV −1X)−1XT Chen et al. (2013); Yan et al.
(2015). It follows that the optimal test statistic is:
Qmin = min[pγ1 , · · · , pγb ] . (3.9)
The p-value for test statistic Qmin is computed through one-dimensional in-
tegration and is described in detail in Lee et al. (2012) Lee et al. (2012). While
SKAT-O has generally been used to test rare variants, both rare and common vari-
ants can be accommodated by using different SNV weights in the burden and
SKAT components Ionita-Laza et al. (2013). In this paper, we set burden weights
w
(b)
SNV = 1/
√
MAFSNV(1−MAFSNV) Madsen & Browning (2009) and rare-variant
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weights w(s)SNV = fBeta(1,25)(MAFSNV)Wu et al. (2011), a Beta(1,25) density evaluated
at the SNV MAF. Our choice of burden weights assume SNVs contribute equally to
trait variance while the SKAT weights give more weight to rare variants.
3.2.5 Simulations for FWER and Power
We perform simulations to compare FWER and power between the Meinshausen
adjustment with Shaffer improvement (Meins) Meinshausen (2008), the Bonferroni
correction using effective number of independent SNVs (Bonf-Meff) Gao et al.
(2008), and our proposed adjustment (Meins-Meff).
Table 3.1: Multiple Testing Adjustments Compared
Method Abbreviation Hierarchy Enforced
Meinshausen with Meff Meins-Meff Yes
Meinshausen Meins Yes
Bonferroni with Meff Bonf-Meff No
We simulate genome-wide SNVs for subjects with the software HAPGEN2 using
reference genomes of European ancestry from the 1000 Genomes Project. Simulated
genetic variants are aggregated by gene or 32kb intergenic windows. Genes are
partitioned into promoter, enhancer, 5’ UTR, 3’ UTR, exon and intron sub-regions.
Intergenic windows are divided into 4kb sub-regions.
We use a score test for single SNVs and SKAT-O for SNV-set tests using the
seqMeta package Arie Voorman (2013) in R version 3.4.3 R Core Team (2017). To
assess FWER control of our method, we pick genes of varying size (10, 20, 50, 100,
200 SNVs) and LD (low, medium, high) and run 5000 simulations for 2000 subjects
and continuous, unassociated trait y iid∼ N(0, 1). In each of these genes, we perform
our procedure at significance level α = 0.05.
We evaluate statistical power over 1000 simulations in the same subjects (N=2000)
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and genes used for estimating FWER. In each gene, we randomly select 10% of
SNVs from two sub-regions to be causal and simulate a continuous, normal trait:
y =
m˜∑
k=1
βkgk + ε (3.10)
where m˜ is the number of causal variants in the gene, βk is the effect of the kth
causal SNV specified as βk = 1√MAFk(1−MAFk) so that they contribute equally to trait
variance Madsen & Browning (2009), and random error ε ∼ N(0, V (ε)) where V (ε)
is fixed so that SNVs explain 1% of the trait variance, R2gene = 1%. We estimate
statistical power of the procedure to detect individual SNV effects.
Because genes can differ greatly in LD structure, we also perform a second
set of simulations where more characteristics of the simulation regions are held
constant. In the secondary simulations, we construct genes with 50 and 100 SNVs
and gene sub-regions with 10 SNVs. We vary LD within the sub-regions (low,
medium, or high) and fix LD between sub-regions at zero. We simulate SNVs using
the approach in Barnett et al. (2017), where a multivariate normal random variable
is thresholded to yield SNVs with a target allele frequency and block exchangeable
LD structure. To evaluate control of FWER, we run 25000 repetitions for 2000
subjects and continuous, unassociated trait y iid∼ N(0, 1), where each gene is tested
at α = 0.05 and α = 0.0025. We assess statistical power in the same genes used for
estimating FWER, using the trait-generating model in equation (3.10). Because our
proposed method jointly tests SNVs in each sub-region, statistical power of our
method should be higher when a sub-region contains more causal SNVs (holding
the proportion of causal SNVs and trait variance explained constant). For these
power simulations, we vary concentration of causal SNVs over the sub-regions—
selecting causal SNVs from 25%, 50%, or 75% of sub-regions—while fixing the
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overall proportion of causal SNVs (10%) and trait variance explained by the gene
(R2gene = 1%) at the same levels used in the previous power simulations.
3.2.6 Analysis in the Framingham Heart Study
We applied our method to data from the Framingham Heart Study (FHS), an ongo-
ing longitudinal cohort study with detailed medical history, physical examinations,
and medical tests Castelli (1984). The first 5209 FHS participants were recruited
from Framingham in 1948 and form the “Original Cohort”. In 1971, offspring of the
Original Cohort and their spouses were also recruited into a second cohort (“Off-
spring”) of 5124 participants. A third generation cohort (“Gen III”) was created in
2002 from grandchildren of the Original Cohort and children of Offspring Cohort
spouses whose parents were not in the Original Cohort (N=4095) Splansky et al.
(2007). While originally developed as a cardiovascular cohort study, FHS has many
other traits, such as fasting glucose and different cancers. In our analysis, we tested
associations between ≥8-hour fasting glucose and SNVs in genes or intergenic
windows.
We used genotypes and traits for 6419 diabetes-free participants from the Off-
spring Cohort at exam 5 and Third Generation Cohort at exam 1. Fasting glucose
residuals were computed within each sex and cohort by regressing fasting glucose
on age and age squared.
Single SNV hypotheses were tested with score tests, while SNV-set tests were
tested with SKAT-O. We used the seqMeta package Arie Voorman (2013) in R
version 3.4.3 R Core Team (2017), which implements the famSKAT method to
account for relatedness between participants Chen et al. (2013). Relatedness between
participants is generally handled within the association test, such that unadjusted
p-values from famSKAT will not be influenced by familial correlation. For this
52
reason, our proposed multiple testing method can be applied to the FHS cohort
without any further modifications.
3.3 Results
3.3.1 Simulation Results in Randomly Selected Genes
Empirical FWER for each method in randomly selected genes is presented in Table
3.2 and Figure 3.3, stratified by gene and LD between SNVs in the genes. The
proposed method controls empirical FWER at α = 0.05 for most genes in our sim-
ulation, with the exception of one gene (M=20) with low LD. Empirical FWER of
our method increases with gene size, being slightly conservative in small genes
(M ≤ 10) and approaching 0.05 in larger genes (M ≥ 100). The Bonf-Meff adjust-
ment has inflated FWER in two genes with low LD (M=20 & 50) but is conservative
in genes with high LD. Meinshausen’s adjustment has very conservative FWER
across all genes due to ignoring LD between SNVs.
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Figure 3.3: Empirical FWER in randomly selected genes for Bonfer-
roni correction with effective number of independent SNVs (Bonf-
Meff), Meinshausen’s method (Meins), and the proposed method
(Meins-Meff). FWER evaluated in 5000 simulations, 2000 subjects,
and randomly selected genes of size M = 10, 20, 50, 100, 200 SNVs.
Gene tests evaluated at significance level α = 0.05. Each panel repre-
sents a different level of LD between SNVs (LD = 1−Meff/M ). No
large genes (M ≥ 100) had low LD. Error-bars are exact 95% binomial
confidence intervals.
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Table 3.2: Empirical FWER, 5000 simulations, N=2000, α = 0.05
Gene Size LD Proposed Method (Meins-Meff) Bonf-MeffFWER (95% CI) FWER/α FWER (95% CI) FWER/α
10
25%
0.035 (0.030, 0.040) 0.69 0.045 (0.04, 0.052) 0.91
20 0.054 (0.048, 0.061) 1.08 0.054 (0.048, 0.061) 1.08
50 0.049 (0.043, 0.056) 0.98 0.053 (0.047, 0.060) 1.06
10
50%
0.042 (0.037, 0.048) 0.84 0.045 (0.039, 0.051) 0.90
20 0.051 (0.045, 0.057) 1.02 0.039 (0.034, 0.045) 0.78
50 0.038 (0.033, 0.044) 0.76 0.042 (0.036, 0.048) 0.83
100 0.043 (0.037, 0.049) 0.85 0.043 (0.038, 0.049) 0.86
200 0.045 (0.039, 0.051) 0.90 0.056 (0.050, 0.063) 1.12
10
75%
0.031 (0.026, 0.036) 0.61 0.03 (0.025, 0.035) 0.59
20 0.041 (0.036, 0.047) 0.83 0.029 (0.024, 0.034) 0.58
50 0.040 (0.035, 0.046) 0.81 0.033 (0.028, 0.038) 0.65
100 0.048 (0.043, 0.055) 0.97 0.029 (0.025, 0.034) 0.58
200 0.047 (0.042, 0.054) 0.95 0.026 (0.022, 0.031) 0.52
Statistical power for the three methods in randomly selected genes are presented
in Figure 3.4. The proposed multiple testing procedure is strictly more powerful
than Meinshausen’s adjustment in all selected genes, regardless of gene size or LD
structure. We expect this result to hold for any gene, as our method relaxes the
significance levels used in Meinshausen’s procedure. Our proposed adjustment is
also at least as powerful as the Bonf-Meff, except in a gene with 50 SNVs in high
LD.
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Figure 3.4: Statistical power in randomly sampled genes for Bonfer-
roni correction with effective number of independent SNVs (Bonf-
Meff), Meinshausen’s method (Meins), and our proposed method
(Meins-Meff). We use 1000 simulations, N=2000, and a gene test
α = 0.05. Each panel represents a different level of LD between SNVs
(LD = 1−Meff/M ). No large genes (M ≥ 100) had low LD. Error-bars
are exact 95% binomial confidence intervals.
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3.3.2 Simulation Results in Genes Simulated with fixed LD structure
Figure 3.5 shows our proposed method also controls FWER in our simulated genes
with fixed LD structure. Our method is less conservative than the Bonf-Meff and
Meinshausen’s method for all levels of LD in the smaller gene (M=50) and in the
larger gene (M=100) when α = 0.05. Meinshausen’s method is more conservative
than the other two methods at higher LD levels (≥ 50%).
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Figure 3.5: Empirical FWER in simulated genes (fixed LD struc-
ture) for Bonferroni correction with effective number of independent
SNVs (Bonf-Meff), Meinshausen’s method (Meins), and our proposed
method (Meins-Meff). FWER evaluated in 25000 simulations, 2000
subjects, and simulated genes with M = 50 or 100 SNVs. Gene tests
evaluated at significance level α = 0.05 and 0.0025.)
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Statistical power for the three methods in simulated genes with fixed LD struc-
ture are presented in Figure 3.6. The proposed multiple testing procedure is strictly
more powerful than Meinshausen’s adjustment in all simulated genes, regardless
of gene size, LD structure, or concentration of causal SNVs within sub-regions. Our
proposed adjustment is at least as powerful as the Bonf-Meff for most simulated
genes, except in small genes (M=50) where SNVs have high LD within sub-regions
(75%) and fewer sub-regions contain causal SNVs (≤ 50%). Relative power of the
three methods are similar in simulated genes (Fig 3.4) and randomly sampled genes
(Fig 3.6), where Bonf-Meff had higher power in gene with 50 SNVs (M=50) and
high LD (75%).
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Figure 3.6: Statistical power in simulated genes (fixed LD structure)
for the Bonferroni with effective number of independent SNVs (Bonf-
Meff), Meinshausen’s method (Meins), and proposed method (Meins-
Meff). We use 1000 simulations, N=2000, and a gene test α = 0.05
for the larger gene M = 100 and α = 0.0025 for the smaller gene.
Error-bars are exact 95% binomial confidence intervals.
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3.3.3 Results in the Framingham Heart Study (FHS)
Our method detects fewer SNVs associated with fasting glucose trait than the Bonf-
Meff correction, identifying only half of SNVs (27/54) that were significant at the
Bonf-Meff significance level of α = 2.5× 10−8. Of these 27 SNVs, 70% had smaller
adjusted p-values with our method than Bonf-Meff. All Bonferroni-significant SNVs
had significant region p-values (see Table 3.3).
Table 3.3: Regional Associations
Chr Start (kbp) Stop (kbp) Nearest Gene (Distance) p-value 1 Overlap 2
2 169752 169780 G6PC2 (0) 5.6× 10−8 80%
7 44183 44229 GCK (0) 1.1× 10−8 0%
7 44240 44253 YKT6 (0) 1.2× 10−8 100%
10 113344 113348 TCF7L2 (1.4mb) 2.6× 10−6 N/A 3
11 92702 92715 MTNR1B (0) 2.2× 10−13 10.5%
1 Minimum region p-value if contiguous regions. 265,174 windows tested, signifi-
cance level for genes = 1.89× 10−7.
2 % overlap between SNVs identified by our proposed method and Bonf-Meff
3 Region with no SNVs significant at Bonf-Meff
Table 3.4 includes SNV associations that were not significant with Bonferroni
or our method but that might be significant with a less conservative regional
adjustment. In particular, rs12781261 on chromosome 10 had a region p-value close
to Bonferroni level (p = 2.6× 10−6 > pBonferroni = 1.9× 10−7) and small unadjusted
p-value (punadj = 1.3× 10−6, padj = 0.697). The SNV rs12781261 resides in enhancer
GH10J111598 which may affect transcription of nearby genes LOC105378486 (52kb
downstream) and RPS6P15 (83kb upstream). The two closest genes have no links
to metabolic traits, but a more distant gene TCF7L2 (1.4mb downstream) has been
implicated in blood homeostasis and is associated with type 2 diabetes Peng et al.
(2012). Several SNVs in the vicinity of rs12781261 are also nominally associated
with insulin sensitivity: rs35395062, rs35032270, rs11003799, rs7075455 (p<0.003).
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Table 3.4: Potential SNV Associations
Chr BP rsID Nearest Gene (Distance) p-valueRaw Gao Proposed
10 111582662 rs12781261 TCF7L2 (1.4mb) 1.3× 10−6 1 0.7 1
1 Adjusted p < 1 indicates a raw p-value within an order of magnitude of the significance
level
3.4 Discussion
In this paper, we present a novel multiple testing adjustment for GWAS that incor-
porates LD between SNVs in a hierarchical testing procedure Meinshausen (2008).
We find in simulations that our proposed method controls FWER at α = 0.05, has
greater power than Meinshausen’s adjustment, and is at least as powerful as Bonf-
Meff when many SNVs are causal (causal proportion = 10%). In our analysis of
fasting glucose in FHS, our method identifies half of SNVs (27/54) significantly
associated with fasting glucose trait at the Bonf-Meff level.
Additionally, we identify a nearly significant association between fasting glucose
and a SNV on chromosome 10 (rs12781261). The SNV rs12781261 resides in an
enhancer of genes LOC105378486 (52kb downstream) and RPS6P15 (83kb upstream).
A plausible connection between fasting glucose and rs12781261 may be TCF7L2
(1.4mb upstream). TCF7L2 has multiple polymorphisms associated with type 2
diabetes Peng et al. (2012), especially the intronic variant rs7903146 (risk allele OR =
1.35) Zhao et al. (2017). Gene TCF7L2 codes for transcription factor 7-like 2 (TCF7L2)
that acts as part of theWnt signaling pathway. Recent work suggests Wnt-signalling
increases risk for diabetes by elevating serotonin expression, as serotonin has been
shown to regulate glucose homeostasis and is elevated in diabetic patients Leiherer
et al. (2018). While there is no evidence linking rs12781261 and TCF7L2, previous
studies have observed variants up to 2mb away from a causative gene Brodie et al.
62
(2016).
The difference between our simulation results and FHS analysis reflects our
choice of simulation parameters and gene-level test. In power simulations, we set
10% of variants causal, have the variants contribute roughly equally to trait variance,
and cap total trait variance explained by SNVs at 1%. Using these parameter values,
our power simulation contained many causal SNVs with small effect on the trait,
leading to less rejected single SNV tests at the Bonf-Meff (significance) level. In our
FHS analysis, a handful of variants had much stronger associations with fasting
glucose than the remaining variants, which may signal a much smaller proportion
of SNVs are causal in fasting glucose than the 10% we used in simulations. For
smaller causal proportions (1%,5%), the Bonf-Meff adjustment or LASSO-based
screening test may perform better than our method implemented with SKAT-O.
Our proposed method may be limited by our definition of SNV-sets and the
hierarchy requirement that SNVs only be tested if SNV-sets containing them are
associated with the trait. In many SNV-sets, SNVs that are unassociated with the
trait will drown out the trait-associated SNVs. When computational resources
are available, adaptive SNV-set tests Urrutia et al. (2016); Klasen et al. (2016) can
be used to detect individual associated SNVs even when combined with many
unassociated SNVs. Furthermore, the significance level for SNV-set tests could be
refined by computing a Bonf-Meff level for set-based tests Xu et al. (2014), or by
incorporating a sequential improvement where rejecting all single-SNV hypotheses
in a SNV-set enables less stringent significance levels for sibling SNV-sets Goeman
& Finos (2012).
In conclusion, we present a novel multiple testing method for GWAS with both
rare and common SNVs. Our proposed multiple testing procedure combines both
rare and common variants to improve power to detect single-variant associations.
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Single SNVs can be tested at a more lenient significance level because FWER is
controlled at the gene-level. The proposed method has greater power than the com-
monly used Bonf-Meff when many SNVs contribute to the trait (causal proportion
pi = 10%). Our biologically-driven SNV groupings also yield interpretable SNV-set
tests. In our FHS analyses, we find a possible association between fasting glucose
and rs12781261, a SNV on chromosome 10 that is nominally associated with insulin
sensitivity and near a gene TCF7L2 associated with type 2 diabetes. Our method
might have better power to detect SNV-trait associations with alternative SNV-set
definitions, such as gene-sets, or different SNV-set tests, such as a LASSO-based
screening test Klasen et al. (2016) with mixed effects LASSO Schelldorfer et al. (2014)
modified for the model in Equation 3.7.
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Chapter 4
Bonferroni-Holm using Effective Number of
Independent Tests with Applications to
Genetic Association Studies
4.1 Introduction
Many traits are heritable, but it is difficult to determine exactly which genetic
variants are influencing these traits. Genome-wide associations studies (GWAS) are
conducted to disentangle the effects of different genetic factors, where each single
nucleotide variant (SNV) is tested for association with a trait. Every test carries
a risk of rejecting the null hypothesis of no trait-SNV association when, in fact, a
SNV has no true effect on trait or disease risk. As a result, testing at a significance
level of α = 0.05 in a GWAS with millions of tests would result in many spurious
associations.
Many multiple testing methods have been developed to control the probability
of a study making at least one type I error, or the family-wise error rate (FWER).
To date, nearly all methods for FWER control in GWAS use hypothesis weighting,
where each hypothesis among a set ofM null hypotheses (H0,1, H0,2, · · · , H0,M ) is
assigned a weight 0 ≤ w1, w2, · · · , wM ≤ 1, and the test for H0,i is rejected if the
p-value of the test, pi ≤ wiα. The traditional Bonferroni correction assigns equal
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weight to each hypothesis, or wi = 1/M for all i, but is known to be conservative
for correlated tests such as in GWAS, where tests are dependent because SNVs in
linkage disequilibrium (or associated with each other in a population) will have
correlated measures of association with a trait. Other works have proposed less
conservative methods for controlling FWER in GWAS, where
∑M
i=1wi ≥ 1, such
as procedures that estimate wi through sample splitting Rubin et al. (2006), derive
optimal wi from distributional assumptions (Gaussian tests) and prior information
Roeder &Wasserman (2009); Darnell et al. (2012); Dobriban et al. (2015), or assign wi
through covariates independent of the p-values under the null hypothesis H0,i such
as genomic distance between a SNP and a ChIP-seq signal Ignatiadis et al. (2016).
The most widely used multiple testing method in GWAS uses the effective number
of independent tests (Meff) to control FWER Hendricks et al. (2014), assigning
wi = 1/Meff for all i. We hereafter refer to this method as the Bonferroni correction
with effective number of independent tests (Bonf-Meff).
In this paper, we present a novel multiple testing method for controlling FWER
in GWAS, which is a sequential rejection procedure based on the Bonf-Meff method.
4.2 Methods
Our proposed method combines the Bonferroni-Holm (BH) procedure with the
effective number of independent tests. We describe the classic BH procedure,
our changes to incorporate the effective number of tests, and then present how it
can be applied to genetic association studies. Our proposed procedure violates
Holm’s sufficient condition, which precludes our use of Holm’s proof technique to
demonstrate strong control of FWER. Therefore, we evaluate our method’s ability
to control FWER control through simulations. We also provide an implementation
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of our method in the context of a hierarchical structure imposing logical relations
among the tests (Appendix B and C).
4.2.1 Classic Bonferroni-Holm Procedure
The BH procedure is a sequential variant of the Bonferroni correction Holm (1979).
Let H0,i be the null hypothesis that all SNVs in set i are unassociated with the trait,
where a set of SNVs may contain a single SNV. ForM SNV-sets, denote the family
of hypotheses by H = {H0,i : i = 1, . . . ,M}; p-values for tests of the hypotheses
by p1, . . . , pM ; set of rejected hypotheses byR ⊆ H; and set size (or cardinality) by
|H| = M . We write the Bonferroni-Holm procedure as:
Algorithm 2: Classic Bonferroni-Holm Correction for SNV-sets
Data: p-values p1, p2, . . . , pM for tests of H0,1, H0,2, . . . , H0,M
1 Initialize (empty) rejection setR = ∅
2 repeat
3 Reject H0,i where mini/∈R pi ≤ α|H\R|
4 Update rejection setR := R∪ {rejectedH0,i}
5 until No new rejections.
Like the Bonferroni correction, the BH procedure is based on Boole’s inequality
and makes no assumptions about the dependence structure of p-values. Both
Bonferroni and BH procedures protect against the ‘worst case’ dependence structure
where all tests are independent. When tests are dependent, however, Bonferroni and
BH corrections are conservative Goeman & Solari (2014). Bonferroni-based multiple
testing procedures can be made less conservative by accounting for correlation
between test statistics.
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4.2.2 FWER Control for Dependent P-values
Correlation between association tests in GWAS can often be determined a priori
from linkage disequilibrium (LD) between SNVs Hendricks et al. (2014). Let CH be
a known correlation matrix for tests t1, t2, . . . , tM of hypotheses H0,1, H0,2, . . . , H0,M .
Multiple testing procedures for GWAS primarily differ in usage of CH to compute
multiplicity adjustments. Conneely and Boehnke (2007) develop a BH procedure
assuming single-SNV association test statistics t = [t1, . . . , tM ] are asymptotically
normal t ∼ N(0, C˜H) under the global null hypothesis
⋂M
i=1H0,i, where C˜H is the
covariance matrix equivalent of CH Conneely & Boehnke (2007). At each iteration of
BH, the minimum p-value of unrejected tests,mini/∈R pi, is evaluated by integrating
over the multivariate normal N(0, C˜H\R).
When the null distribution of the minimum p-value is unknown, permutation-
based procedures can be used to compute critical values empirically, such as the
minP or maxT methods of Westfall and Young (1993) Westfall & Young (1993). In a
permutation test, the null distribution of the minimum p-value is approximated by
randomly reassigning the observed traits and recomputing the minimum p-value
for each permutation of trait values. Permutations are computationally burdensome
and are difficult to implement for dependent individuals, such as relatives in the
Framingham Heart Study.
An alternative approach is to compute the effective number of independent tests,
meff, and test all hypotheses at significance level α/meff. When all SNVs are perfectly
correlated, for example, all hypotheses can be tested at significance level α rather
than Bonferroni level α/M . We refer to this approach as the Bonferroni correction
with effective number of independent tests (Bonf-Meff) and use the implementation
of Gao et al. (2008) Gao et al. (2008), wheremeff is the fewest number of eigenvalues
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explaining ≥ 99.5% of variation in CH. WhenH includes all tests in a GWAS,meff
is roughly 106, corresponding to a genome-wide significance level of α = 5× 10−8
Pe’er et al. (2008).
4.2.3 Proposed Bonferroni-Holm Procedure with Effective Number of Inde-
pendent Tests (BH-Meff)
We propose a Bonferroni-Holm procedure that uses the effective number of in-
dependent tests (BH-Meff). Denote the number of tests of hypotheses S ⊆ H
by |S| = MS , correlation matrix between tests by CS , and eigenvalues of CS by
λ1 ≥ λ2 ≥ . . . ≥ λMS ≥ 0. When only single-SNV null hypotheses are tested, as in
GWAS for common variants, CH is the correlation matrix for the SNVs being tested.
As in Gao et al. Gao et al. (2008), denote the effective number of independent tests
|S|eff = mS as fewest number of eigenvalues explaining at least (1 − ) × 100% of
variation in CS :
|S|eff = mS = argmin
j
{
j∑
i=1
λi ≥ (1− )MS} . (4.1)
Parameter  ∈ [0, 1) should be a small, positive value to ignore vanishingly
small eigenvalues (λi ≈ 0) introduced by sampling variation (in the between-
test correlation matrix) and numerical imprecision. In this paper, we follow the
recommendation of Gao et al. and set  = 0.005, where ≥ 99.5% of variation in
CS is explained Gao et al. (2008). To date, no other work in GWAS has examined
other choices for , e.g. as a function of sample size. Gao et al. justified their
choice of  by comparing their multiple correction thresholds to those estimated
from a permutation null distribution (using simulated common SNPs). A previous
numerical study has also verified Gao’s choice of  = 0.005 controls FWER under
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various SNV correlation structures Halle et al. (2016), while several other methods
based on eigenvalues Nyholt (2004); Li & Ji (2005); Galwey (2009) were sometimes
anti-conservative.
Here, we incorporate the effective number of independent tests into the BH
correction as follows. At each step of the BH procedure, the correlation matrix
for all tests CH has submatrices of correlations between rejected tests CR and
between unrejected tests CH\R on the block diagonal. Off-diagonals of CH contain
correlations between rejected and unrejected tests, which we denote by submatrices
R01, R
T
01.
CH =
CH\R R01
RT01 CR
 (4.2)
The classic BH weight is the (reciprocal of) number of unrejected tests: 1/|H \R|
or, equivalently, 1/(|H| − |R|). When rejected tests are correlated with unrejected
tests, however, |H \ R|eff 6= (|H|eff − |R|eff). We propose using |H|eff − |R|eff as an
estimator for the number of remaining independent tests. The intuition is that
falsely rejected tests of hypotheses inRmay be correlated with tests of unrejected
hypothesesH \R. To avoid penalizing the same error twice, |H|eff − |R|eff removes
all rejected tests (and subsequently false positives incurred) from the BH correction.
We propose a Bonferroni-Holm correction with effective number of independent
tests (BH-Meff) as follows:
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Algorithm 3: Bonferroni-Holm with Effective Number of Independent SNVs
Data: SNV-sets, S, with null hypothesesH = {H0,1, H0,2, . . . , H0,M}
Test statistics t1, t2, . . . , tM forH
P-values p1, p2, . . . , pM of tests
Correlation between tests CH
1 Initialize (empty) rejection setR = ∅
2 repeat
3 Compute the number of remaining independent tests: m0 = |H|eff − |R|eff
4 Ifm0 = 0, stop and reject all remaining H0,i
5 Reject all H0,i where pi ≤ 1m0α
6 Update rejection setR := R∪ {rejected H0,i}
7 until No new rejections
By using the effective number of unrejected tests, m0, we violate a sufficient
condition that Holm used to guarantee FWER control of the BH procedure. Hy-
potheses are added to the rejection set when the p-values of their corresponding
tests are below the significance level. As a consequence, the remaining number
of independent tests, m0 = |H|eff − |R|eff, will depend on p-values. Therefore, a
proof of FWER strong control cannot be derived in analogy to that of the classic BH
procedure. Instead, we evaluate FWER control through simulation.
The dependence of BH-Meff weightm0 on p-values violates Holm’s sufficient
(but not necessary) condition that weights are independent of the p-values of the
tests Holm (1979). Other studies have demonstrated FWER control under weak
dependence between weights and p-values Chen et al. (2015). In our application to
SNV-set tests, we only use BH-Meff to control FWER over tests at the gene-level
or higher, where we would also expect weak dependence between weights and
71
p-values. Few SNVs in a gene will be in strong LD with SNVs in other genes.
Another departure of our proposed method from the classic BH is in the sum of
weightsm0. Unlike the weights used in the BH method, our proposed weights at
each iteration do not sum to 1. We assess FWER control in simulations using a
variety of dependence structures.
4.2.4 Simulations for FWER and Power
We evaluate FWER and statistical power of our proposed BH-Meff method and the
Bonf-Meff method Gao et al. (2008) in simulated genes.
Table 4.1: Multiple Testing Methods Compared
Method Hypotheses Novel
Bonferroni-Holm with Meff (BH-Meff) single-SNV Yes
Bonferroni with with Meff (Bonf-Meff) single-SNV No
We simulate genes with different size (M=10, 25, or 50 SNVs), LD level (R2
between each SNV in gene = 10%, 25%, 50%), and level of positive dependence
between SNVs (100% of SNV correlations are positive, 75% of correlations are
positive and 25% are negative). SNVs are generated by thresholding a multivariate
normal random variable with block exchangeable correlation matrix Barnett et al.
(2017), such that each SNV has minor allele frequency (MAF) is 0.3, all SNVs
are in HardyWeinberg equilibrium Salanti et al. (2005), and correlation between
SNVs match the target level of LD and positive dependence. In each gene, we run
10000 simulations for 5000 subjects using a continuous normally distributed trait
y
iid∼ N(0, 1) that is unassociated with SNVs.
We compare statistical power between the methods for different proportions of
causal SNVs (pi = 0.1, 0.25, 0.5) and different effect sizes among the causal variants
(uniform, linear differences, or exponential differences) using a total of 1000 simula-
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tion replicates for each gene. In each gene, we randomly select M˜ = pi ×M causal
SNVs and simulate a continuous trait:
y =
M˜∑
k=1
βkgk + ε (4.3)
where βk is the effect of the kth causal SNV specified as βk = 1 for the scenario with
uniform effects (SNVs contribute equally to the trait), βk = k for the scenario where
effect sizes differ linearly (some SNVs contribute more to the trait), and βk = e
3
(k−1)
(m−1)
for the scenario where effect sizes differ exponentially (a few SNVs contribute most
of the trait variance, βm ≈ 20 × β1). The random error ε is normally distributed,
ε ∼ N(0, σ2e), where σ2e is fixed so that causal SNVs from each gene jointly explain
1% of the trait variance (R2gene = 1%).
Association tests for SNVs are conducted with score tests. For a model without
covariate adjustments, the score statistic for variant k is S2k = [
∑n
i=1(yi − y¯)gik]2,
where yi is the trait value of the ith subject and gik is the number of minor alleles
of SNV k carried by subject i. Under the null hypothesis, S2k is asymptotically
distributed χ21 and unadjusted p-values are computed from quantiles of a χ21 dis-
tribution. Both FWER and power are evaluated for α = 0.05. All procedures and
computations are performed in R version 3.4.3 R Core Team (2017).
4.2.5 Analysis in the Framingham Heart Study (FHS)
We use our method to study SNV associations with fasting glucose in FHS. We
include diabetes-free participants from the Offspring Cohort at exam 5 and Third
Generation Cohort at exam 1. Fasting glucose residuals were computed within each
sex and cohort by regressing fasting glucose on age and age squared.
We restrict our analysis to several candidate genes that have a biological con-
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Table 4.2: Candidate Genes Selected for Analysis in FHS
Gene CHR Pos (center) Relation to Fasting Glucose Reference
SPC25 2 168,873,752 previous GWAS Ellis et al. (2015)
G6PC2 2 168,905,620 glucose homeostasis, insulin secretory function Ng (2016)
ABCB11 2 168,975,194 lipid metabolism and liver functions Arab et al. (2017)
ADCY5 3 123,366,027 couples glucose to insulin secretion in human islets Hodson et al. (2014)
SRD5A1 5 6,653,864 affects serum insulin Rył et al. (2017)
GCK 7 44,171,220 phosphorylation of glucose Petersen et al. (2017)
YKT6 7 44,207,631 adjacent to GCK, previous GWAS Nagy et al. (2017)
MTNR1B 11 92,977,931 glucose metabolism, insulin, circadian rhythms Hu & Jia (2016)
nection to fasting glucose. In simulations, our proposed method has greater power
than the Bonf-Meff correction when pi > 0.1, but the two corrections are very similar
when pi ≤ 0.1. In a GWAS for common variants, very few SNVs are expected to
be causal, so the two methods will be very similar. In candidate genes, however,
we can expect a reasonable proportion of SNVs to be associated with the trait, and
our method finds trait-SNV associations that were not detected by the Bonf-Meff
method.
The earliest candidate gene studies predate GWAS and, like the first generation
of GWAS, were often underpowered, leading to few associations being replicated
Farrell et al. (2015). In addition, genes were often selected as candidates based
on weak biological evidence. More recent candidate gene studies have been used
as part of GWAS meta-analyses or used for studying pleiotropic effects of SNVs
in genes that affect multiple phenotypes, particularly for mental health disorders
where sample sizes are small Luo et al. (2016); Amare et al. (2017). Advances in
high-throughput technology have also greatly improved understanding of gene
functions, enabling better selection of candidate genes. In Table 4.2, we present the
candidate genes examined in our analysis of fasting glucose, along with justification
for their inclusion.
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4.3 Results
4.3.1 Simulation Results
Our proposed method (BH-Meff) and Bonf-Meff controlled FWER in all simulated
genes and LD structures (Figure 4.1). Both methods were slightly conservative in
all genes except in the large gene (M=50) with non-positive dependence (Figure
4.2). Our proposed method was less conservative than Bonf-Meff in all simulated
genes, regardless of LD structure.
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Figure 4.1: Empirical FWER for Bonferroni correction with effective
number of independent SNVs (Bonf-Meff) and our proposed method
(BH-Meff). We use 10000 simulations, 5000 subjects, and simulated
genes of size M = 10, 25, 50 SNVs with different LD structure (level
of LD and level of positive dependence between SNVs). Each panel
represents a different level of LD between SNVs. FWER is evaluated
for α = 0.05. Error-bars are exact 95% binomial confidence intervals.
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Figure 4.2: Empirical FWER for Bonferroni correction with effective
number of independent SNVs (Bonf-Meff) and proposed method
(BH-Meff). We use 10000 simulations, 5000 subjects, and simulated
genes of size M = 10, 25, 50 SNVs, averaged over LD levels. The top
panel shows genes with both positively and negatively correlated
SNVs, where 75% of SNVs are positively correlated with all other
SNVs and 25% of SNVs are negatively correlated with all other SNVs.
The bottom panel shows genes with only positively correlated SNVs.
FWER is evaluated for α = 0.05. Error-bars are exact 95% binomial
confidence intervals.
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Statistical power for both methods varied little under the different scenarios
for SNV effect sizes, thus we present results averaged over the different effect
size scenarios and stratified by key simulation parameters: causal SNV proportion
pi (Figures 4.3,4.4,4.5), number of SNVs M (Figure 4.3), level of LD (Figure 4.4),
and positive dependence between SNVs (Figure 4.5). Overall, power of both
methods was lower for higher causal SNV proportions pi because we constrained
trait variance explained to 1%, i.e. more causal SNVs explain less trait variance
per SNV. In all simulated genes, our proposed method (BH-Meff) was at least as
powerful as the Bonf-Meff method, and was substantially more powerful than
Bonf-Meff when the causal SNV proportion was large (pi ≥ 0.25).
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Figure 4.3 shows our proposed method was more powerful than Bonf-Meff in
genes with both a high proportion of causal SNVs (pi ≥ 0.25) and more than 25
SNVs. In genes with lower causal proportion (pi = 0.1), both methods had similar
power.
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Figure 4.3: Statistical power for Bonferroni correction with effec-
tive number of independent SNVs (Bonf-Meff) and our proposed
method (BH-Meff). We use 2700 simulations, varied sample sizes
(N = 100, · · · , 5000), and simulated genes of size M = 10, 25, 50 SNVs.
Statistical power was averaged over different LD structures. Each
panel represents a different combination of causal SNV proportion (pi)
and number of SNVs (M ). Power is evaluated at α = 0.05. Error-bars
are exact 95% binomial confidence intervals.
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Figure 4.4 shows our proposed method was more powerful than Bonf-Meff in
genes with a high proportion of causal SNVs (pi ≥ 0.25), regardless of LD. Both
methods had lower power in genes with less LD.
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Figure 4.4: Statistical power for Bonferroni correction with effec-
tive number of independent SNVs (Bonf-Meff) and our proposed
method (BH-Meff). We use 2700 simulations, varied sample size
(N = 100, · · · , 5000), and simulated genes with low LD (10%), mod-
erate LD (25%), and high LD (50%). Statistical power was averaged
over different gene sizes M = 10, 25, 50 SNVs. Each panel represents a
different combination of causal SNV proportion (pi) and LD. Power
evaluated at α = 0.05. Error-bars are exact 95% binomial confidence
intervals.
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Figure 4.5 shows our proposed method was more powerful than Bonf-Meff
in genes containing only positively correlated SNVs (bottom panel). Power was
much lower for both methods in genes containing both positively and negatively
correlated SNVs (top panel). Both methods had comparable power in genes with
causal proportion pi ≤ 0.25 and non-positive dependent SNVs.
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Figure 4.5: Statistical power for Bonferroni correction with effective
number of independent SNVs (Bonf-Meff) and proposed method
(BH-Meff). We use 2700 simulations, varied sample size (N =
100, · · · , 5000), and simulated genes. The top three panels show power
in simulated genes with both positively and negatively correlated
SNVs—75% of SNVs are positive correlated with all other SNVs and
25% of SNVs are negatively correlated. The bottom three panels show
power in simulated genes with only positively correlated SNVs. Sta-
tistical power was averaged over gene sizes and levels of LD. Each
panel represents a different combination of pi and proportion of posi-
tively correlated SNVs. Power is evaluated at α = 0.05. Error-bars are
exact 95% binomial confidence intervals.
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4.3.2 Results in the Framingham Heart Study (FHS)
In our candidate gene analysis of fasting glucose in the FHS, 94 out of 384 SNV
associations were significant using the Bonf-Meff method, and 99 SNVs were signif-
icant using the BH-Meff method. The additional five associations identified by our
method are presented in Table 4.3.
The five SNVs uniquely identified by our method are located in introns and,
to the best of our knowledge, have no clear biological link to fasting glucose.
However, all of the SNVs have been reported in other studies. The SNVs in G6PC2
(rs3821117) and SPC25 (rs10497345, rs11688384) were significantly associated with
fasting glucose (p = 5.5 × 10−27, 3.7 × 10−16, and 1.1 × 10−12 respectively) in the
Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) GWAS
Scott et al. (2012). SPC25 variant rs11688384 was also found to be associated with
height in the recent GIANT UK Biobank GWAS (p = 5.4× 10−22) Yengo et al. (2018).
Of the SNVs in ADCY5, rs6794936 was significantly associated with type II diabetes
or T2D (p = 1.8 × 10−11) and rs9870651 was significantly associated with BMI
p = 1.9 × 10−8 in a recent GWAS in the DIAbetes Meta-ANalysis of Trans-Ethnic
association studies (DIAMANTE) consortium Mahajan et al. (2018).
Table 4.3: Significant SNV Associations with Fasting Glucose in FHS
CHR Gene SNP Major / MAF P-value Significance LevelMinor Bonf-Meff BH-Meff
2 G6PC2 rs3821117 T/C 0.101 6.04× 10−4
4.27× 10−4
6.33× 10−4
2 SPC25 rs10497345 G/C 0.045 4.72× 10−4 6.25× 10−4
2 SPC25 rs11688384 T/A 0.171 6.20× 10−4 6.33× 10−4
3 ADCY5 rs6794936 T/A 0.484 4.31× 10−4 6.17× 10−4
3 ADCY5 rs9870651 G/T 0.398 4.99× 10−4 6.25× 10−4
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4.4 Discussion
In this paper, we present a novel sequential testing procedure, BH-Meff, for control-
ling FWER in genetic association studies. Our method controls FWER and is at least
as powerful as Bonf-Meff method in simulations with many different LD structures.
In FHS, we demonstrate the utility of our method in a candidate gene study for
fasting glucose. Our method identifies five intronic SNVs associated with fasting
glucose that were not detected by the Bonf-Meff method. Three SNVs in G6PC2 and
SPC25 have been identified in previous GWAS for fasting glucose Scott et al. (2012),
one SNV was found to be associated with height Yengo et al. (2018), and the two
SNVs in ADCY5 were found associated with T2D and BMI Mahajan et al. (2018).
Further analysis needed to validate these results, possibly using a more diverse set
of candidate genes and meta-analyzing results across multiple studies.
Like all methods for FWER control using the effective number of independent
tests (Meff), our method has not been proven to control FWER under all possible
correlation structures for tests. Optimistic estimators for Meff can lead to inflated
FWER in some situations Halle et al. (2016). For this reason, we chose one of the
most conservative estimators of Meff Gao et al. (2008) and demonstrated FWER
control in simulations for a number of different correlation structures.
Our proposed method is at least as powerful as the Bonf-Meff method, but
only has greater power when a large proportion SNVs are causal (pi > 0.1). In a
full GWAS, few SNVs are expected to be causal and our BH-Meff correction will
be virtually identical to the Bonf-Meff correction. To improve the power of our
method in these cases, we suggest aggregating SNVs into SNV-sets. We present a
hierarchical testing procedure for our method in Appendix B, which jointly tests
SNVs and SNV-sets and may have greater power to detect single SNV associations
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in a GWAS. We also present several options for joint tests of SNV-sets in Appendix
C.
In conclusion, we present a flexible multiple testing adjustment, BH-Meff, for
genetic association studies. BH-Meff has small computational footprint, requiring
only one eigenvalue decomposition to compute the effective number of independent
SNVs remaining at each iteration. In the worst case, BH-Meff runs in polynomial
time and scales in the number of tests with unadjusted p-value < 0.05, or roughly
O([0.05M ]3). BH-Meff is more powerful than the Bonf-Meff method for controlling
FWER when many null hypotheses are false, such as in candidate gene studies, and
is equivalent to a Bonf-Meff correction in GWAS. Another promising application for
our method may be phenome-wide association studies (PheWAS), which examine
the association between a given SNV and all available phenotypes Verma et al.
(2019). The SNVs used in PheWAS are generally selected from previous GWAS for
a single trait and, as such, are more likely to be associated with multiple traits than
the average SNV. Hence, the causal proportion of SNVs in a PheWAS (pi) is likely
much higher than in a GWAS, which are ideal conditions for our proposed method.
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Chapter 5
Conclusion
5.1 Summary
Genome-wise association studies have discovered many genetic variants associated
with complex traits but can explain only a fraction of complex trait heritability.
Further advances in statistical methodology will be required to fully uncover the
genetic architecture of complex traits and the biological mechanisms underlying
trait associations with individual variants.
In this thesis, we present novel approaches for identifying rare variants and
other variants that are difficult to detect in traditional GWAS. In Chapter 2, we
extend SKAT to optimized convex combinations of SKAT statistics to incorporate
different sources of prior biological information on SNVs. We hope our method will
facilitate identification of rare variants and integration of functional genomic anno-
tation in set-based tests. In Chapter 3, we present a multiple testing procedure for
jointly testing single SNVs and groups of SNVs (SNV-sets) with common biological
function. We incorporate correlation between SNVs (in sets) in Meinshausen’s tree-
based testing procedure, enabling less stringent significance levels for SNV tests. In
Chapter 4, we develop a sequential improvement for the Bonferroni correction with
effective number of independent tests, which is commonly used to control FWER in
GWAS, and a tree-based implementation of our sequential method that is tailored
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for GWAS. We hope our proposed methods will accelerate discovery of variants
that are difficult to detect in traditional GWAS.
In the remainder of this chapter, we will discuss limitations of our proposed
methods and possible directions for future work.
5.2 Limitations and Possible Future Work
In Chapter 2, we demonstrated the utility of combining functional genomic annota-
tions in SKAT when trait information is used to optimize the combination. Several
opportunities for future improvements are evident from our simulations and FHS
analysis. We observed in simulations that empirical power of our test, cSKAT,
increased with the level of independence between annotation classes. In Chapter 2,
we pre-selected annotations that were linked to the trait in biomedical literature, but
we could further improve cSKAT by pre-processing annotations, such as creating
independent annotation classes with principal components analysis (PCA) (Jolliffe,
2014). The composite annotation classes would need to be constructed so that the
corresponding cSKAT weights could be interpreted in terms of the original annota-
tions. For example, the relative importance of SNVs located at histone modifications
could be computed as a sum of cSKATweights for annotation principal components
(PCs) times the loading for histone modification on each annotation component.
Another potential area of improvement is the computation of p-values. We
proposed evaluating the cSKAT statistic through data-splitting, where we optimize
weights on a small subset of data and test SNV-sets with optimized weights on the
remaining data. The test could be further improved by using the same data for both
estimating kernel weights and testing, provided an asymptotic null distribution can
be found for the optimized test statistic. To do so, we would need to characterize
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eigenvalues of optimized kernel matrix in terms of the convex weights.
In Chapter 3, we developed a sequential testing procedure for jointly testing
SNVs and SNV-sets that incorporates correlation between SNVs. By only testing
SNVs in SNV-sets associated with the trait, single-SNV tests were tested at less
stringent significance levels. The hierarchy requirement implies power of our
method to detect individual variants depends strongly on power of the SNV-set test.
Thus, the most promising direction for future work would be developing a better
joint test for SNV-sets. An omnibus test of multiple SNV-set tests, as described
in Barnett et al. (Barnett et al., 2017), would make our testing adjustment less
dependent on any one test and more useful for testing more diverse SNV-sets.
For example, we could use the minimum p-value of SKAT (Wu et al., 2011) and
GHC (Barnett et al., 2017) tests on a SNV-set, then use resampling to evaluate the
minimum p-value.
We could also make further improvements to our construction of SNV-sets
for the multiple testing procedure. We constructed a testing adjustment for tree-
structured hypotheses, and thus tested only non-overlapping SNV-sets. In doing so,
we may have lower power to detect causal SNVs located at the edge of a SNV-set
that are in high LD with SNVs in other SNV-sets. To better handle the boundary
problem, our testing adjustment could be reformulated for hypotheses in a directed
acyclic graph (DAG) where SNVs can belong to multiple SNV-sets, such as in the
graphical testing procedure proposed by Meijer et al. (Meijer et al., 2015).
In Chapter 4, we developed a sequential multiple testing procedure for corre-
lated SNV tests (BH-Meff) and used the procedure to control FWER in a candidate
gene study. We also proposed a tree-based procedure using our method, which
jointly tested chromosomes, genes, and SNVs. Our proposed BH-Meff method was
limited by the proportion of causal variants. We could further investigate other
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SNV aggregation strategies and joint tests to improve power of our method.
We would like to make one last remark about the estimator for number of
independent tests, which was used in Chapters 3 and 4 to incorporate correlation
between tests in the multiple testing adjustments. Many estimators for the number
of independent single-SNV tests are available, and the Bonf-Meff method based
on these estimators is widely used to control FWER in GWAS. To the best of our
knowledge, however, no work has shown that any of these estimators converge to
the true number of independent tests. An investigation of the asymptotic properties
of these estimators might facilitate the development of more powerful multiple
testing procedures for GWAS.
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Appendix A
cSKAT Optimization
Existing rare variant tests with adaptive annotation selection use the minimum
p-value over annotations. Two such tests have been developed for SKAT (Urrutia
et al., 2016) and SKAT-O (He et al., 2017), where the test statistic is the minimum
p-value among SKAT(-O) statistics computed for each annotation. Denote pQ` as
the p-value for the SKAT(-O) statistic using the `th annotation. The minP statistic is:
T = minp pQ1 , pQ2 , · · · pQ` . (A.1)
The significance of the T statistic can be evaluated analytically. The minimum
p-value approach performs well but scales poorly to combinations of annotation,
where p-values must be computed for a grid of combination weights γ and nu-
merical integration is required to compute the p-value of T . On the other hand,
maximizing combinations of test statistics without accounting for their p-values
results in poor power (Zhan et al., 2017). In our application, adding SNVs to a
SNV-set would increase the test statistic but also increase the eigenvalues of the
kernel matrix. Intuitively, rescaling kernel test statistics by their kernel matrix
eigenvalues could help connect test statistic maximization to p-value minimization.
For example, the null distribution of a SKAT statistic rescaled by its eigenvalues
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can be approximated through the Satterthwaite approach (Lumley, 2011):
Q
‖λ‖2
approx∼ aχ2v (A.2)
where scale parameter a = ‖λ‖2‖λ‖1 and degrees of freedom v = (
‖λ‖1
‖λ‖2 )
2 are ratios of the
l1 and l2 norms of the kernel matrix eigenvalues λ. Thus, increasing eigenvalues
will increase the scale but decrease the degrees of freedom.
To incorporate multiple sources of annotation, we optimize a convex combina-
tion of SKAT statistics, Qγ =
∑L
`=1 γ`Q`, where the eigenvalues λ of test statistic Qγ
depend on the convex weights γ. We show that maximizing Qγ/‖λ‖2 is equivalent
to maximizing centered alignment A between trait y and convex combination ker-
nel Kγ for continuous trait with no non-genetic covariates. For continuous trait,
the cSKAT statistic can be rewritten as Qγ = σˆ−20 yTPKγPy where projection matrix
P = In − X(XTX)−1XT . When there are no non-genetic covariates, P is simply
a centering matrix (In − 1n1Tnn ) and, assuming all candidate kernels are centered,
the cSKAT statistic reduces to Qγ = σˆ−20 yTKγy. Let 〈. , .〉F and ‖.‖F denote the
Frobenius inner product and norm, and the centered kernel-target alignment be
A(yyT , Kγ) = 〈yy
T ,
∑L
`=1 γ`K`〉F
‖yyT ‖F ‖Kγ‖F . Then observe:
Qγ
‖λ‖2 ∝
yTKγy√∑J
j=1 λ
2
j
=
tr(yyT
∑L
`=1 γ`K`)√
tr(K2γ)
∝ 〈yy
T ,
∑L
`=1 γ`K`〉F
‖yyT‖F ‖Kγ‖F = A(yy
T , Kγ).
(A.3)
Hence, maximizing the cSKAT statistic scaled by its eigenvalues is equivalent
to maximizing the centered kernel target alignment between trait and convex
combination kernel:
argmax
γ
Qγ
‖λ‖2 = argmaxγ A(yy
T , Kγ) . (A.4)
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When there are non-genetic covariates, the optimal convex weights for a trait
maximize the kernel-target alignment between the residuals of trait regressed on
non-genetic covariates (e = y − yˆ0) and the centered convex combination kernel
(Kγ =
∑L
`=1 γ`K`):
γ = argmax
γ
〈eeT , Kγ〉F
‖Kγ‖F . (A.5)
Let a be the vector of inner products between residuals and centered candidate
kernels, a = (〈eeT , K1〉F , · · · , 〈eeT , K`〉F )T , and let M denote the matrix of inner
products between candidate kernels, i.e. Mjk = 〈Kj, Kk〉F . Then the optimal convex
weights, γ = v/‖v‖, are the solution to the following Quadratic Programming (QP)
problem:
min
v≥0
vTMv − 2vTa . (A.6)
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Appendix B
Tree-based Bonf-Meff Procedure
In our previous work (Chapter 2), we developed a tree-based testing procedure
based on the effective number of independent SNVs (Meins-Meff). We aggregated
SNVs into sets with common biology (e.g. genes) and only tested SNVs in SNV-sets
that were jointly associated with the trait. By enforcing this hierarchy, individual
SNVs could be tested at less stringent significance levels. A key limitation of our
previous method was the multiple testing adjustment for SNV-set tests.
Here, we present a tree-based testing procedure for GWAS using our proposed
BH-Meff adjustment. We construct a tree T from SNVs in each chromosome. Each
tree consists of a root node (chromosome), genes or 4kb windows, and individual
SNVs as leaves. Let SNVs in a chromosome be indexed by i = 1, . . . ,M with
corresponding null hypothesesH = {H0,i : i = 1, . . . ,M}. A schematic is presented
in Figure B.1.
The null hypothesis for a SNV-set, S ⊆ {1, . . . ,M}, is true when all SNVs in the
set are unassociated with the trait:
H0,S =
⋂
i∈S
H0,i . (B.1)
The tree is constructed such that every pair of SNV-sets (S, S ′ ∈ T ) either have
no intersection (S ∩ S ′ = ∅) or one SNV-set is a subset of the other (S ⊆ S ′). The
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Figure B.1: Tree of hypotheses in chromosome
parent of SNV-set S, or pa(S), is the smallest SNV-set in T that contains S. Similarly,
children of S, or ch(S), are all subsets S ′ ⊂ S pre-specified in T . Siblings of S, or
si(S) = ch(pa(S)) \ S, are all other children of the parent of S. We write the p-value
for test of H0,S as pS , p-values for all SNVs in the set as {pi}i∈S , and multiplicity-
adjusted significance levels for SNVs and SNV-set as αi and αS , respectively. We
present a tree-based testing procedure in Algorithm 4, which applies our BH-Meff
correction to each level of the tree separately. Our procedure uses BH-Meff to
adjust significance levels for tests of top level hypotheses. Whenever a hypothesis
is rejected, the adjusted significance level for the rejected hypothesis is passed its
children.
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Algorithm 4: Proposed Tree-based BH-Meff Algorithm
Data: Trait, y
Genotype or dosage matrix for SNVs, G
Tree for each chromosome T1, T2, . . . , T23
Genes or windows, S, with multiple SNVs. One set S for each Chromosome
1 Initialize (empty) rejection setRT = ∅
2 Define chromosome null hypothesesH := {H0,T1 , . . . , H0,T23}
3 for Chromosomes 1, 2, . . . , 23 do
4 Jointly test association between SNVs in chromosome i (GTi) and trait (y)
5 Compute unadjusted chromosome p-value: pi
6 end
7 repeat
8 Compute the number of remaining independent tests: m0 = |H|eff−|RT |eff
9 Ifm0 = 0, stop and reject all remaining H0,i
10 Reject all H0,Ti where pi ≤ αi = 1m0α
11 Update rejection setRT := RT ∪ {rejected H0,Ti}
12 until No new rejections
13 for each Ti ∈ RT do
14 Assign significance level αi used to reject H0,Ti
15 Initialize (empty) rejection setRS = ∅
16 Set SNV-set hypotheses (for genes and intergenic windows)
H := {H0,S}S∈Ti
17 Compute unadjusted p-values for SNV-set hypotheses, pS
18 repeat
19 Compute the number of remaining independent tests:
m0 = |H|eff − |RS|eff
20 Ifm0 = 0, stop and reject all remaining H0,S
21 Reject all H0,S where pS ≤ αS = 1m0αi
22 Update rejection setRS := RS ∪ {rejected H0,S}
23 until No new rejections
24 Reject all H0,SNV where pSNV ≤ αS AND pa(SNV ) ∈ RS
25 end
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Appendix C
Association Tests for SNV-sets
Our proposed BH-Meff method can be applied joint tests of association between
sets of SNVs and a trait. In this section, we describe different joint tests that could
be paired with BH-Meff. Testing the joint effect of all SNVs in large SNV-sets is a
challenging problem because the number of SNVs are an order of magnitude larger
than the sample size (M ≈ 106  N ). To date, two different high-dimensional
testing approaches have been developed for testing SNV-sets in GWAS: marginal
methods that aggregate marginal test statistics or effects of individual SNVs Wu
et al. (2011); Barnett et al. (2017), and post-selection inference methods that select
SNVs with non-zero effects after regularization with LASSO and test the hypotheses
of selected SNVs Lockhart et al. (2014); Lee et al. (2016); Buzdugan et al. (2016a);
Klasen et al. (2016); Shah & Bühlmann (2018).
Of the marginal methods, the Sequence Kernel Association Test (SKAT) Wu et al.
(2011) has been used most often in GWAS (see Chapters 1 and 2). In the SKAT
approach, a linear mixed model is specified with fixed effects β for non-genetic
covariates X and a subject-level random effect b ∼ N(0, τK) for genetic effects,
where τ indexes the trait variance explained by all SNVs in the SNV-set and K is a
pre-specified covariance matrix with entries Kij measuring the genetic similarity
between subjects i and j (i, j ∈ {1, · · · , N}). SKAT is a variance component score
test of the hypothesis τ = 0. The SKAT statistic is Q = (y − yˆ0)TK(y − yˆ0)/σˆ20 ,
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where yˆ0 is the predicted trait from non-genetic covariates and σˆ20 is a maximum
likelihood estimate of trait variance under H0. The null distribution of Q is a
weighted sum of independent χ2 variables,
∑J
j=1 λjχ
2
1, where λj are eigenvalues of
P
1
2KP
1
2 , P = I −X(XTX)−1XT is the variance of residuals (y − yˆ0), and I is an
(n× n) identity matrix.
There are two barriers to using SKAT to test a large number of SNVs (M >
105). First, computing eigenvalues of P
1
2KP
1
2 requires O(min[N3,M3]) operations
or O(MNk) if the number of leading eigenvalues k is known a priori. Second,
power of the SKAT depends heavily on the linkage disequilibrium between trait-
associated SNVs and SNVs that are unassociated with the trait Barnett et al. (2017).
Our FHS analysis using SKAT in Chapter 2 was limited in this manner, failing
to detect a number of SNV associations that were significant at the Bonf-Meff
level 5× 10−8. Another test, the Generalized Higher Criticism (GHC) Barnett et al.
(2017), is less reliant on LD with trait-associated SNVs. The GHC statistic is a
sum of thresholded single-SNV test statistics: if a SNV test statistic exceeds a fixed
threshold, it contributes 1 to the sum and 0 otherwise. The GHC method selects a
threshold that maximizes a standardized version of the sum. Barnett et al. present
a method for computing the GHC p-value after optimizing the threshold Barnett
et al. (2017). When testing all SNVs in a chromosome (M > 106), GHC will be
substantially less computationally efficient than SKAT. Due to the limitations of
marginal methods for large SNV-set tests, hypotheses for SNV-sets much larger than
genes should be avoided, e.g. replace chromosomes in Figure B.1 with pathways.
In our application, we adopt the LASSO-based testing procedure used by Klasen
et al. and Buzdugan et al. for GWAS Klasen et al. (2016); Buzdugan et al. (2016a). In
both papers, separate halves of the data are used to select SNVs (Nselection = N/2)
and to test null hypotheses of selected SNVs (Ntest = N/2). A linear model relating
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trait to SNVs in the SNV-set without interactions is specified as follows (excluding
non-genetic covariates for notational convenience):
y = µ+Gβ∗ +  (C.1)
with (N ×1) vector y of (continuous) trait values for theN subjects, (N ×M) design
matrix G of genotypes where gij is the ith subject’s genotype for the jth variant
(0 ≤ Gij ≤ 2), and (N × 1) vector  of normally distributed errors i ∼ N(0, σ2).
Parameter µ is the intercept and β∗ is the (M × 1) vector of true effects for each SNV
(truth denoted by superscript ‘*’), respectively.
The goal is to test the null hypothesis that all SNVs in the SNV-set are unas-
sociated with the trait (H0 : β∗ = 0). In the post-selection inference framework
based on LASSO, this is accomplished by first estimating β and then testing all
SNV hypotheses corresponding to non-zero estimated coefficients. Denote the
LASSO Tibshirani (1996) estimator of β∗ by βˆ. In LASSO regression, βˆ is chosen to
minimize the penalized likelihood:
βˆ = argminβ (y −Gβ)′(y −Gβ)/N + λ
M∑
j=1
|βj| (C.2)
where λ > 0 is a regularization parameter usually chosen tominimizemean-squared
error in cross-validation. Here, we have excluded µ by assuming y is mean-centered
and columns of G have been standardized. In LASSO regression, λ penalizes the
L1-norm of SNV effects (
∑M
j=1 |βj|) and consequently leads to a sparse βˆ with many
βˆj = 0.
The set of SNVs with non-zero (true) effects is called the active set S∗ = {j : β∗j 6=
0}. The aim of variable-screening methods is to find an active set of SNVs relatively
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close to the truth (Sˆ ≈ S∗), such that H∗0 : β∗j = 0, for all j ∈ S∗ is equivalent
to testing H0 : βˆj = 0 for all j ∈ Sˆ(λ). When screening with LASSO, the active
set estimator is a function of hyperparameter λ: Sˆ(λ) = {j : βˆj(λ) 6= 0}. Several
promising methods have been developed for testing H0 Lockhart et al. (2014); Lee
et al. (2016); Shah & Bühlmann (2018) on the same data used to tune λ. However,
they have yet to be extended to subjects with correlated trait values and cannot be
used in our application to FHS with related individuals.
To accommodate related individuals in FHS, we use a multiple sample-splitting
approach Meinshausen et al. (2009); Buzdugan et al. (2016a); Klasen et al. (2016)
with families. We perform B repetitions of the data-splitting strategy defined in
Chapter 1. The procedure is as follows. For b = 1, · · · , B:
1. Randomly partition families of related individuals into independent training
and test sets of size N (b)train and N
(b)
test.
2. Use LASSO to select SNVs in the training set (N (b)train). Denote the set of selected
SNVs by Sˆ(b) ⊆ {1, · · · ,M}.
3. Construct a mixed model with familial correlation for the trait in the test set
(N (b)test) including only active SNVs Sˆ(b)
4. Compute F-test statistic for selected SNVs in the test set, t(b) and corresponding
p-value p(b)
5. Repeat steps 1-4 B times.
6. Compute aggregate p-value over splits as follows:
p = min{1, (1− log(γmin) inf
γ∈(γmin,1)
Q(γ)} (C.3)
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where Q(γ) = min{1, qγ({p(b)/γ; b = 1, · · · , B})}, γ ∈ (0, 1), γmin = 0.05, and
qγ(·) is the empirical γ-quantile function.
For BH-Meff, we compute correlation between LASSO-based tests of separate
SNV-sets from the sample splits. Denote the test statistics for SNV-set Sj over
multiple test sets by tj = [t
(1)
j , t
(2)
j , · · · , t(B)j ]. Then we define entries of the sample
correlation matrix for all tests CH as follows:
(CH)jk =
∑B
b=1(t
(b)
j − t¯j)(t(b)k − t¯k)√∑B
b=1(t
(b)
j − t¯j)2
∑B
b=1(t
(b)
k − t¯k)2
(C.4)
We can then use the estimated correlation matrix in our proposed BH-Meff
method.
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